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ABSTRACT 
 
Glioma  represents  one  of  the  deadliest  primary  CNS  tumours.  We  used  a 
transgenic  spontaneous  astrocytoma  mouse  model  to  analyse  glioma-immune 
system interactions at the peripheral level. Importantly, this model allows analyses 
at early (asymptomatic) stages of the disease without the influence of concomitant 
treatments. In patients, local immunosuppression is induced by soluble factors and 
cell-associated molecules; in the periphery, T-cell hyporesponsiveness to in vitro 
mitogen-stimulation and a decreased CD4/CD8 T cell ratio were demonstrated. 
We performed functional and quantitative analyses on mouse LN and spleen cells 
to determine whether mice exhibit immunosuppression. In contrast to a parallel 
study of local immune status, there was little alteration in immune function or 
phenotype at early stages of tumour development. However, certain trends were 
apparent in symptomatic mice, and the CD4/CD8 ratio was significantly reduced. 
Furthermore, we used a recombinant  virus vaccination  to  elicit or enhance an 
antigen-specific immune response. Although there was no significant difference 
between groups, a modest trend to have greater response in transgenic rather than 
control mice was observed. Overall, differently to local immune status, limited 
peripheral immune defects were restricted to later disease stages. Moreover, there 
were no significant alterations in specific immune response in transgenic mice. 
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RIASSUNTO 
 
 
Glioma. Il glioma, tumore maligno alle cellule gliali, è uno tra i più comuni e 
mortali  tumori  primari  al  cervello.  Anche  a  seguito  di  intervento  chirurgico  e 
chemio-radioterapia, la prognosi rimane limitata a meno di due anni. Esistono 
quattro differenti tipologie di glioma, secondo il tipo cellulare predominante di cui 
esso  è  composto:  astrocitoma,  ependimoma,  oligodendroglioma  e 
oligoastrocitoma.  L’origine  del  glioma  rimane  ancora  incerta;  due  meccanismi 
sono stati proposti per spiegare l’origine del tumore: la trasformazione di cellule 
staminali  endogene  e  il  de-differenziamento  di  astrociti  maturi.  A  livello 
istologico,  il  glioma  è  caratterizzato  da  pleomorfismo  nucleare,  alta  densità 
cellulare, figure mitotiche, necrosi e proliferazione dell’endotelio vascolare. Un 
aspetto peculiare di questo tipo di tumore ￨ l’eterogeneità. Esso ￨ inoltre molto 
invasivo  e  risulta  costituito  da  cellule  necrotiche  circondate  da  una  massa  ad 
elevata  attività  angiogenica.  A  differenza  di  altri  tumori  solidi,  il  glioma  non 
metastatizza al di fuori del sistema nervoso centrale. Esso viene classificato in 
quattro  gradi,  secondo  la  gravità  crescente  della  patologia  (classificazione 
dell’Organizzazione Mondiale della Sanità, 2007): I grado, caratterizzato da basso 
potenziale proliferativo e di possibile cura tramite resezione chirurgica; II grado, 
ricorrente  e  anch’esso  interessato  da  basso  potenziale  proliferativo;  III  grado, 
tumore maligno contraddistinto da atipia nucleare; IV grado, definito glioblastoma 
multiforme,  associato  ad  alta  attività  mitotica,  elevata  malignità  e  prognosi 
infausta. Vengono distinte due tipologie di glioblastoma multiforme: glioblastoma 
primario, il quale si sviluppa de novo in un periodo mediamente inferiore ai tre 
mesi, e secondario, il quale è la conseguenza di una lenta progressione da glioma 
di II o di III grado. Differenti mutazioni genetiche caratterizzano i due tipi di 
glioblastoma multiforme, supportando l’ipotesi che diversi meccanismi molecolari 
portano  allo  sviluppo  di  essi.  Tuttavia,  caratteristiche  istologiche  e  risposta  al 
trattamento sono comparabili tra i due.    
 
Immunologia  tumorale.  In  questo  lavoro  sperimentale,  è  stata  in  particolare  
studiata l’interazione tra tumore e sistema immunitario. Essa ￨ stata recentemente 
designata  dall’ipotesi  dell’immunoediting,  processo  suddiviso  in  tre  fasi 
temporaneamente  conseguenti:  eliminazione,  equilibrio  e  fuga.  Nella  fase  di 
eliminazione, il sistema immunitario individua ed elimina il tumore; nella seconda 
fase, si instaura un equilibrio dinamico tra i componenti del sistema immunitario e 
le  cellule  tumorali,  le  quali  accumulano  mutazioni  genetiche  ma  la  loro 
proliferazione risulta limitata. Nell’ultima fase, si verifica progressione tumorale, 6 
 
grazie  alla  presenza  di  cellule  tumorali  resistenti,  selezionate  durante  la  fase 
precedente.  Inoltre, il tumore a questo  ultimo stadio  è in  grado di  influenzare 
negativamente l’azione del sistema immunitario (immunosoppressione tumorale). 
E’  ampiamente  riconosciuto  che  a  livello  cerebrale  l’interazione  tra  sistema 
immunitario  e  tumore  è  specializzata  ed  unica.  In  passato,  il  cervello  era 
considerato un organo immunologicamente “privilegiato”, a causa dell’esistenza 
della barriera emato-encefalica, della mancanza di convenzionali vasi linfatici e 
della  presenza  di  diversi  fattori  immunosoppressivi.  Diversi  studi  hanno 
dimostrato  che  cellule  del  sistema  immunitario  possono  infiltrare  la  massa 
tumorale.  Il  cervello  è  ora  considerato  un  organo  immunologicamente 
“specializzato”. 
 
Immunosoppressione  locale  associata  al  glioma.  I  meccanismi 
immunosoppressivi associati al glioma possono essere divisi in passivi ed attivi. 
La  cellula  tumorale  può  sottrarsi  attivamente  al  riconoscimento  da  parte  del 
sistema  immunitario  sottoesprimendo  le  molecole  MHC  I.  Essa  può  indurre 
inoltre apoptosi di cellule immunitarie esprimendo FasL sulla membrana cellulare. 
Inoltre,  l’ipossia  caratterizzante  il  microambiente  tumorale  contribuisce  a 
sopprimere le normali funzioni delle cellule del sistema immunitario. Le cellule 
tumorali possono inoltre secernere fattori solubili immunosoppressivi come IL-10 
e TGF-β (immunosoppressione passiva). Le cellule T regolatrici (Treg) rivestono 
infine  un  ruolo  essenziale  nell’immunosoppressione.  Esse  possono  secernere 
citochine  inibitorie  e/o  modulare  la  funzionalità  delle  cellule  presentanti 
l’antigene. Inoltre, possono presentare citotossicità. 
  
Immunosoppressione  periferica  associata  al  glioma?  In  questo  lavoro 
sperimentale, abbiamo analizzato se il glioma può indurre immunosoppressione 
anche  a  livello  periferico.  Per  questo  scopo,  abbiamo  utilizzato  un  modello 
murino di astrocitoma. Il modello utilizzato è transgenico e sviluppa il tumore in 
modo  spontaneo,  riproducendo  quello  che  avviene  nell’uomo.  E’  stato  infatti 
dimostrato che le mutazioni genetiche e l’eterogeneità del modello riproducono la 
progressione e le caratteristiche del glioma umano. Inoltre, il transgene contiene il 
gene  LacZ,  il  quale  codifica  per  un  antigene  conosciuto  (β-galattosidasi), 
considerato un antigene tumore-associato.  
Studi  su  pazienti  affetti  da  glioma  hanno  dimostrato  diverse  disfunzioni  nella 
risposta  immunitaria  a  livello  periferico;  una  conseguenza  di  queste  è  la 
dimostrata anergia cutanea a comuni antigeni batterici. Inoltre, è stato osservato 
che alcuni tipi cellulari del sistema immunitario di pazienti malati sono affetti da 
anomalie  a  livello  quantitativo  e  funzionale.  In  particolare,  il  rapporto  T 7 
 
linfocitario CD4/CD8 risulta diminuito; inoltre, la responsività dei linfociti T alla 
stimolazione  in  vitro  con  mitogeno  risulta  ridotta.  Non  sono  invece  state 
dimostrate alterazioni nelle proporzioni dei linfociti B. E’ però da considerare il 
fatto  che  questi  studi  non  hanno  valutato  la  possibile  concomitante  terapia 
somministrata ai pazienti analizzati e sono stati effettuati solamente durante gli 
ultimi,  sintomatici  stadi  della  malattia.  L’utilizzo  di  un  modello  risulta 
vantaggioso principalmente perch￩ permette lo studio dell’immunologia tumorale 
anche ai primi stadi della malattia e l’analisi del modello evita l’influenza che il 
trattamento terapeutico ha sul sistema immunitario. 
 
In  questo  lavoro  sperimentale,  abbiamo  determinato  quantitativamente  diverse 
tipologie di cellule immunitarie in milza e linfonodi inguinali, per determinare se 
significative alterazioni interessano i  topi portatori di tumore. Abbiamo inoltre 
eseguito un test in vitro, per analizzare se la risposta dei linfociti T splenici alla 
stimolazione  con  mitogeno  è  diminuita  come  osservato  nei  pazienti.  Infine, 
abbiamo indagato la capacità di attivazione dei linfociti T in topi transgenici, dopo 
vaccinazione  con  un  virus  ricombinante.  Abbiamo  inoltre  analizzato  la  loro 
risposta specifica in vivo ad un antigene tumore-associato. 
 
Stato  immunologico  periferico  nel  modello  spontaneo  di  astrocitoma. 
Abbiamo osservato che il bilancio immunologico non è alterato a partire dai primi 
stadi  della  malattia,  ma  solo  nelle  ultime  fasi  della  progressione  tumorale.  Il 
rapporto T linfocitario CD4/CD8 è infatti risultato significativamente diminuito 
solo nel topo malato. Abbiamo inoltre dimostrato che le cellule soppressive di 
origine  mieloide  (gruppo  eterogeneo  di  cellule  immunosoppressive)  non  sono 
presenti in aumentate quantità a livello splenico in topi affetti da glioma, come 
invece dimostrato in altri modelli. Come osservato nell’uomo, anche nel modello 
murino di glioma la porzione periferica dei linfociti B non risulta alterata. La 
risposta dei linfociti T alla stimolazione in vitro si è dimostrata mitogeno dose-
dipendente. Non abbiamo osservato iporesponsività dei linfociti T provenienti da 
topi  malati,  ma  è  da  considerare  il  fatto  che  il  test  eseguito  è  in  vitro  e  di 
conseguenza  non  è  stato  riprodotto  lo  stesso  ambiente  immunosoppressivo 
presente  in  vivo.  Recenti  studi  hanno  infatti  dimostrato  una  correlazione  tra 
presenza del glioma e anormalità dei linfociti T. Abbiamo infine eseguito una 
vaccinazione con un virus ricombinante: VV-LacZ. Abbiamo analizzato in primo 
luogo la capacità dei linfociti di attivarsi. Nel  topo transgenico, la capacità di 
attivazione  delle  suddette  cellule  non  risulta  diminuita.  Non  è  stata  invece 
osservata una risposta specifica all’antigene tumore-associato nei topi transgenici, 
dopo  vaccinazione  e  stimolazione  in  vitro.  Da  discutere  ￨  l’efficienza  dello 8 
 
strumento di vaccinazione utilizzato, il quale ￨ stato dimostrato susciti un’elevata 
risposta  virus-specifica  ed  una  modesta  risposta  immunologica  rivolta  verso  il 
gene codificato nel costrutto. Infine, la stimolazione in vitro è stata effettuata con 
due differenti peptidi dell’antigene e da esaminare ￨ la loro immunogenicità. 
 
Conclusioni. Abbiamo dimostrato che la presenza del glioma non influenza in 
modo significativo lo stato immunologico periferico del modello di astrocitoma 
utilizzato, eccetto durante gli ultimi stadi della malattia (quando la porzione di 
linfociti T CD4 risulta compromessa). Inoltre, non abbiamo osservato alterazioni 
nella responsività e nella capacità di attivazione dei linfociti T in topi affetti dal 
tumore. Nel contesto del  glioma umano, coi dati ottenuti si può ipotizzare  che 
l’immunoterapia è efficace solo se somministrata nelle prime fasi del tumore. La 
risposta  immunologica  specifica  anti-glioma  deve  evidentemente  avvenire  a 
livello  locale,  e  questo  aspetto  può  rappresentare  un  fattore  limitante  per 
l’efficacia clinica della vaccinazione terapeutica testata.  
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ABBREVIATIONS 
 
ACK: ammonium cloridium lysis buffer 
Ag : antigen 
APC : antigen-presenting cell 
BBB : blood-brain barrier 
BTSCs : brain tumour stem cells 
CFSE : carboxyfluorescein succinimidyl ester 
cLN : cervical lymph node 
CNS : central nervous system 
ConA : concanavalin A 
CTL : cytotoxic T lymphocyte 
DC : dentritic cell 
EGFR : epidermal growth factor receptor 
FasL : Fas Ligand 
FCS : fetal calf serum 
FWB : flow cytometer wash buffer 
FWB fix : flow cytometer wash buffer with fixative 
GBM : glioblastoma 
GFAP : glial fibrillary acidic protein 
GIM : glioma-infiltrated macrophages 
HBSS medium : Hanks Balanced Salt Solution 
IL : interleukin 
Iono : ionomicyn 
LN : lymph node 
MDSCs : myeloid-derived suppressor cells 
MHC : major histocompatibility complex 
NK : natural killer  
NTG : non transgenic 
PCR : polymerase chain reaction 
PGE2 : prostaglandin E2 
PMA : phorbol 12-myristate 13-acetate 
RasB8 mice : GFAP-V
12 HA-ras B8 mice 
RPMI : Roswell Park Memorial Institute medium 
SD : standard deviation 
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TAAs : tumour-associated antigens 
TG : transgenic 
TGF-β : transforming growth factor β 
Th2 : T helper type 2 
TLR : toll-like receptor 
Th1 : T-helper type 1 
TMZ : temozolomide 
TNF : tumour necrosis factor 
Treg cells: regulatory T cells 
VEGF: vascular endothelial growth factor 
VEGFR : vascular endothelial growth factor receptor 
VV : Vaccinia virus 
WHO : World Health Organization 
wo : week-old 
βgal : β-galactosidase 
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1. INTRODUCTION 
 
1.1. GLIOMA 
 
1.1.1. Classification, histopathology and origin of glioma 
 
Glioma,  a  malignant  tumour  affecting  glial  cells,  presents  some  of  the 
greatest challenges in the management of cancer patients worldwide. Even with 
aggressive surgical  resections,  along with  recent  advances  in  radiotherapy and 
chemotherapy, the prognosis for patients remains very poor (Kanu et al., 2009).  
The  World  Health  Organization  (WHO)  published  in  2007  the  fourth 
edition of the Classification of Tumours of the Central Nervous System (CNS), in 
which the categorization and the different grades of tumours are clearly described 
(Louis et al., 2007). The classification is relevant in terms of possible therapies 
and  possible  outcome.  It  permits  also  to  have  a  worldwide  definition  of  the 
tumour, based on histopathological  and  clinical  diagnostic  criteria, in  order to 
permit  epidemiological  studies  and  clinical  trials  without  considering  national 
boundaries. There are four different types of glioma: astrocytoma, ependymoma, 
oligodendroglioma and oligoastrocytoma. In the brain, glial cells are non-neural 
cells that perform several essential functions, such as anchoring to neurons and 
regulating  the  trafficking  of  molecules  and  ions  through  them  (astrocytes), 
covering  the  cavities  of  the  CNS  (ependymal  cells)  and  forming  myelin 
(oligodendrocytes).  The  WHO  classification,  depending  on  the  presence  of 
histological features of malignancy, divides tumours in four different prognostic 
grades. The grade I tumours are surgically curable tumours with low proliferative 
potential, grade II show low-grade malignancy and are infiltrative, grade III are 
malignant and require radio and/or chemotherapy. 
Glioma  usually  manifests  itself  as  a  focal  lesion  with  central  necrosis 
surrounded by  an angiogenic tumour rim; it can be roughly separated  into an 
angiogenic component and an invasive or migratory one. Migration of glioma 
cells in brain parenchyma relatively far away from the tumour core is common, 
complicating surgery and radiotherapy (Kanu et al., 2009). In Wen et al. (2008), 
the  histological  features  of  malignant  glioma  were  described.  Nuclear 
pleomorphism, dense cellularity, mitotic figures, pseudopalisading necrosis and 
vascular endothelial proliferation are observed. Heterogeneity is considered one of 
the hallmark characteristics of the tumour. Unlike other solid tumours, glioma 
rarely metastasizes to locations out of the CNS (de Vries, 2009). 
Recently, studies about the cell of origin of brain tumours have stimulated 
new hypotheses. The discovery of the presence of a small subpopulation of brain 12 
 
tumour stem cells (BTSCs) has led to the hypothesis that neural stem cells are the 
candidate cells of origin of CNS tumours. In Vescovi et al., BTSCs are defined 
through different  characteristics:  they are pluripotent  cells  with  extensive self-
renewal  ability  in  vivo  and  ex  vivo,  they  have  genetic  alterations,  aberrant 
differentiation  properties,  capacity  to  generate  non-tumourigenic  as  well  as 
tumourigenic cells and have cancer-initiating ability upon orthotopic implantation. 
Two  different  mechanisms  have  been  proposed  to  explain  the  origin  of  the 
tumour: either the de-differentiation of mature astrocytes or the transformation of 
the  endogenous  neural  stem  cell  population.  The  presence  of  the  cell  surface 
marker  CD133  on  BTSCs  has  lately  been  reported  and  different  studies  have 
demonstrated correlation between the CD133 cells and the resistance of tumour to 
chemo  and  radio  therapies  (Vescovi  et  al.,  2006).  Although  widely  used,  the 
validation of CD133 as a unique glioma stem cell marker is debated. Recent data 
show that CD133
+ and CD133
- cells share similar tumourigenic properties and the 
isolation of the formers lacks  of specificity (Clement et  al.,  2009). Therefore, 
additional characterization of the functional role of BTSCs is needed to better 
understand tumour initiation, progression and resistance to treatment.  
 
1.1.2. Human Glioblastoma Multiforme: an overview 
 
Glioblastoma multiforme (hereafter GBM or glioblastoma) is one of the 
commonest  brain  tumours  and  one  of  the  deadliest  ones.  It  is  an  invasive, 
aggressive  and  neurologically  destructive  astrocytoma.  It  is  characterised  by  a 
very poor median survival, which has only marginally improved over last several 
decades,  despite  new  technologies  and  different  treatments  used.  In  the  most 
favourable situations and with standard treatments, less than 10% of patients can 
survive  longer  than  five  years  (Stupp  et  al.,  2009).  GBM  is  a  grade  IV 
astrocytoma:  highly  malignant,  mitotically  active,  necrosis-prone  neoplasm 
typically associated with fatal outcome (Louis et al., 2007).  
Glioblastoma can be separated into two main subtypes, on the basis of 
genetic differences and of the median age distribution, even if they are largely 
comparable  from  the  histological  point  of  view  and  they  respond  similarly  to 
conventional therapies (Wen et al., 2008; Ohgaki and Kleihues, 2009). Primary 
glioblastoma  typically  occurs  in  patients  of  mean  age  of  62  years,  whereas 
Secondary GBM occurs on average in 45 years-old patients (de Vries et al., 2009). 
Primary tumours are de novo tumours, which show a clinical history of a period < 
3 months (68% of cases). Secondary GBM develop more slowly from low-grade 
astrocytoma (WHO grade II) or from anaplastic astrocytoma (WHO grade III) 
(figure 1). In the first case, the mean time of progression is estimated to be 5.1 13 
 
years, for the second case 1.9 years. Progression from WHO grade II through 
WHO grade III to grade IV GBM is also possible (Kanu et al., 2009). 
 
 
 
 
Figure 1: Primary and Secondary Glioblastoma. Glioma is hypothesised to derive from brain 
tumour  stem  cells  (BTSCs)  or  from  de-differentiated  mature  astrocytes.  In  this  figure,  two 
different pathways leading to Primary and Secondary Glioblastoma are shown. Primary GBM are 
de  novo  tumours,  whereas  Secondary  GBM  derive  from  low-grade  astrocytoma  and/or  from 
anaplastic astrocytoma. 
 
 
In the United States and in the European countries, the annual incidence of 
total Primary and Secondary malignant glioma is estimated to be 5 per 10,000 
person-years  (Wen  et  al.,  2008).  The  aetiology  of  the  tumour  is  likely  to  be 
multifactorial; genetic and environmental factors can influence the outcome of the 
tumour.  Suspected  predisposing  factors  are  exposure  to  therapeutic  ionizing 
radiation  and  chemical  carcinogens.  Only  the  first  one  recently  has  been 
statistically proven (Kanu et al., 2009). The adverse prognostic factors include 
advanced  age.  Other  factors  are  histological  features  of  glioblastoma  and 
unresectable tumour. Furthermore, glioblastoma is more common in men than in 
women  and  in  whites  than  in  blacks  (Wen  et  al.,  2008).  The  symptoms  are 
different  and  include  peritumoural  edema,  venous  thromboembolism,  seizures, 
fatigue, memory loss, confusion, personality changes, focal neurologic deficits, 
high intracranial pressure, headaches that when severe may be associated with 14 
 
nausea and vomiting (Wen et al., 2008; Kanu et al., 2009). Generally, the tumour 
progression  is  accompanied  by  symptoms  and  preventative  screening  is  not 
considered useful for asymptomatic patients. The diagnosis is usually performed 
using magnetic resonance imaging (MRI); when MRI is not possible, computed 
tomography scan is useful, even if remains inferior in image detail. Furthermore, 
positron  emission  tomography,  magnetic  resonance  perfusion  and  magnetic 
resonance  spectroscopy  can  be  used  to  delineate  levels  of  metabolites  and  to 
discriminate malignant tumour from benign lesion (Wen et al., 2008; Kanu et al., 
2009). 
It  is  well-known  that  neoplasms  occur  as  a  consequence  of  successive 
accidental  mutational  events;  generally,  the  alterations  concern  signalling 
pathways  and  cell-cycle  regulation.  In  particular,  oncogenes  and  tumour-
suppressor genes play an important role in carcinogenesis; the activation of the 
former and the deactivation of the latter favour glioma evolution. Many molecular 
studies have been performed in order to have a better understanding of the genetic 
mutations in glioma cells. These can help to identify new therapeutic targets and, 
consequently,  to  develop  new,  more  efficient  therapies.  From  the  molecular 
profiles point of view, Primary and Secondary glioblastoma are different and are 
believed to derive from two different genetic pathways (Martinez and Esteller, 
2010). Many different  genetic mutations  characterise the tumour, but  only the 
main ones are considered in this section (table 1). 
 The epithelial growth factor-receptor (EGFR) becomes activated through 
the  binding  of  its  ligand  EGF;  afterwards  the  complex 
EGFR/RAS/NF1/PTEN/PI3K  signalling  pathway  is  initiated,  resulting  in  cell 
proliferation and increased cell survival. EGFR gene overexpression is generally 
observed in Primary GBM (approximately 40%), but it is very rare in Secondary 
tumours  (Ohgaki  and  Kleihues,  2009).  The  most  common  mutated  variant  of 
EGFR that has been identified is EGFRvIII; the resulting defective receptor is 
constitutively activated (Ohgaki and Kleihues, 2009; Kanu et al., 2009; Wen et 
al., 2009). Even if high levels of RAS-GTP have been documented in primary 
tumours, specific mutations affecting RAS in GBM have not been detected. RAS 
overexpression  is  likely  to  be  caused  by  upstream  factors  or  by  the  loss-of-
function  of  the  neurofibromatosis  1  (NF1)  gene,  which  encodes  for  the 
neurofibromin  protein,  a  RAS  negative  regulator  (Kanu  et  al.,  2009).  RAS 
synergy with other signalling pathways is relevant to give rise to glioma (Munoz 
et  al.,  2009).  Inactivation  of  the  PTEN  gene,  a  tumour-suppressor  gene  that 
regulates the PI3K pathway, is more common in Primary glioblastoma (40%) than 
in  Secondary  (Wen  et  al.,  2008).  The  TP53/MDM2/MDM4/p14
ARF  pathway  is 
another  important  pathway  involved  in  the  evolution  of  glioma  (Ohgaki  and 15 
 
Kleihues, 2009). Notably, TP53 gene encodes a protein that promotes cell cycle 
arrest  or  apoptosis  in  response  to  DNA  damage,  hypoxia  or  cell  cycle 
abnormalities.  It  is  essential  for  cellular  and  genetic  stability.  TP53  induces 
transcription of genes such as p21, which prevents the progression through G1 
cell cycle phase into S cell cycle phase. Unlike EGFR and PTEN mutations, TP53 
alterations are more frequent in Secondary than in Primary glioblastoma. TP53 
mutations observed in the two different subtypes of glioblastoma are diverse and 
this suggests, as previously stated, that the acquisition of genetic alterations may 
result from dissimilar molecular mechanisms. RB1 controls the transition from G1 
into the S phase of the cell cycle by inhibiting the action of elongation factor 2 
(E2F), and its expression is in general altered in glioma cells (Kanu et al., 2009). 
One of the most frequent mutations in GBM is loss of heterozygosity (LOH) on 
chromosome 10q, very common in both of glioblastoma subtypes (Martinez and 
Esteller, 2010; Ohgaki and Kleihues, 2009). The IDH1 gene encodes isocitrate 
dehydrogenase  1,  the  enzyme  that  catalyses  the  oxidative  carboxylation  of 
isocitrate to α-ketogluatrate in the Krebs cycle. When mutated, the enzyme loses 
affinity for its substrate. In low-grade astrocytoma and in Secondary glioblastoma, 
IDH1  is  frequently  mutated  (>  80%);  in  contrast,  in  Primary  glioblastoma 
mutations are rare (< 5%). As Ohgaki and Kleihues (2009) explain, this can be 
additional evidence of the possible different origins of the two subtypes of glioma. 
Vascular endothelial growth factor receptor (VEGFR) is over expressed both in 
Primary and Secondary GBM (Wen et al., 2008). 
   
 
Genetic and epigenetic mutations  Primary GBM  Secondary GBM 
EGFR overexpression  40%  rare 
PTEN inactivation  40%  rare 
TP53 alteration  rare  frequent 
LOH 10q  5%  80% 
VEGFR overexpression  frequent  frequent 
MGMT methylation  36%  75% 
 
 
Table 1: Genetic and epigenetic mutations in Primary and Secondary GBM.  All different 
mutations  mentioned  in  this  section  are  listed.  Interestingly,  alterations  observed  in  the  two 
different kinds of GBM are different. This suggests that different molecular mechanisms lead to 
different types of GBM, although histology and therapy response is largely comparable between 
the two.  
 
 16 
 
Epigenetics are also important in glioma evolution (Martinez and Esteller, 
2010).  An  explicative  example  of  a  regulator  gene  undergoing  methylation-
mediated inactivation in glioblastoma is the DNA repair gene O
6-methylguanine-
DNA  methyl  transferase  MGMT),  which  removes  promutagenic  alkyl  groups 
from O
6-methylguanine. Reduction or loss of MGMT activity can occur due to the 
promoter methylation and is associated with improved response to chemotherapy 
and better prognosis (Ohgaki and Kleihues, 2009). Methylation is more frequently 
observed in Secondary GBM (75%) than in Primary GBM (36%); in Secondary 
GBM  is  often  associated  with  TP53  mutations  (Martinez  and  Esteller,  2010). 
Martinez and Esteller (2010) have underlined another important epigenetic change 
that has to been taken into consideration: the expression level of certain micro 
RNA. Recent studies have shown that miR-21 has a higher expression in GBM in 
comparison with normal brain; moreover, downregulation of miR-21 in glioma 
cells can lead to reduction of their invasive capacity. 
 
1.1.3. Glioblastoma prognosis and standard treatment 
 
The  current  standard  of  care  for  GBM  patients  is  maximum  surgical 
resection  if  feasible,  followed  by  radiotherapy  and  concomitant  systemic 
temozolomide  (TMZ)  chemotherapy.  TMZ  is  an  oral  alkylating  agent  with 
antitumor activity and it can cross the blood-brain barrier (BBB) (Kanu et al., 
2009). Notably, Stupp  et  al.  (2009) performed  a clinical trial on  glioblastoma 
patients,  in  which  radiotherapy  alone  is  compared  to  radiotherapy  and 
concomitant  TMZ  chemotherapy  followed  by  adjuvant  TMZ  chemotherapy 
(figure 2). The median survival benefit with chemo-radiotherapy is statistically 
significant  and  clinically  meaningful;  chemo-radio  is  considered  preferable  to 
radiotherapy alone. Toxic effects of the currently used therapy include nausea, 
leucopoenia, anemia, thrombocytopenia, fatigue and severe infections, but all of 
them  are  considered  acceptable  (Stupp  et  al.,  2009).  The  poorly  efficacious 
outcome of the  currently  used treatment  can be explained by diverse  reasons. 
BTSCs seem to be remarkably resistant to radio and chemo therapies, probably 
owing to their hallmark genomic profile (Kanu et al., 2009). Furthermore, the 
standard TMZ chemotherapy fails due to the presence of MGMT (see section 
1.1.2.). Recently, combinations of TMZ with MGMT inhibitors and inhibitors of 
other repair enzymes have studied, in order to improve the efficacy of this therapy 
(Kanu et al., 2009; Wen et al., 2008). 
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Figure 2: Survival curve of patients treated with combined chemo-radiotherapy. (Reproduced 
from Stupp et al., 2009). Survival curve in glioblastoma patients treated with radiotherapy alone 
versus  glioblastoma  patients  treated  with  radiotherapy  with  concomitant  and  adjuvant 
temozolomide  chemotherapy.  Survival  is  greater  with  combined  treatment:  a  few  patients  in 
favourable prognostic categories survive longer than 5 years. 
 
 
Other  different  therapies  are  at  present  investigated,  to  improve  the 
prognosis  and  to  ameliorate  the  quality  of  life  of  glioblastoma  patients. 
Bevacizumab  (Avastin
®
),  a  monoclonal  antibody  against  vascular  endothelial 
growth factor (VEGF), combined with irinotecan, a chemotherapeutic agent, is a 
new chemotherapy protocol increasingly used for recurrent malignant glioma. To 
consider  is  that  this  combined  treatment  has  many  side-effects,  such  as 
thromboembolic complications and gastrointestinal toxicities (Xu et al., 2010). 
Other  types  of  treatment  under  investigation  are  targeted  molecular 
therapy,  such  as  anti-EGFR  therapy,  immunotherapy  (discussed  in  detailed  in 
section 1.3.6.) and gene therapy; additionally, drugs to overcome resistance are 
studied. Combinations of different kinds of therapy are required, due to the fact 
that several pathways can be concurrently altered in glioma cells, which are very 
heterogenic and may manifest different types of alterations and different capacity 
of resistance (Kanu et al., 2009).  
 
1.2. CANCER AND IMMUNOLOGY 
 
Most  information  about  the  interaction  between  cancer  and  immune 
system  has  come  from  tumours  in  sites  other  than  the  brain.  In  the  past,  the 
hypothesis of “immunosurveillance”, which is the detection and elimination of 
tumour cells by the immune system, has been proposed. Different studies have 
been performed in immunodeficient mice strains to prove the correlation with the 18 
 
lack of components of immune system and the develop of the tumour (Swann and 
Smith, 2007). Nevertheless, evidence of immunosurveillance is rare in clinical 
settings (Bui and Schreiber, 2007). The concept of “immunosurveillance” has left 
room for a refined theory, named “immunoediting”, which consists of a process 
divided into three different phases: elimination, equilibrium and escape (Bui and 
Schreiber, 2007; Swann and Smith, 2007) (figure 3). The elimination corresponds 
to the mechanism previously described by the “immunosurveillance” theory. After 
that, a phase of dynamic equilibrium is thought to be established, in which tumour 
cells can continue to evolve and they probably can accumulate genetic changes. 
The third phase is characterised by the progression of the tumour, which is now 
able to resist the action of the immune system, probably thanks to the selection of 
specific resistance tumour cells variants (Swann and Smith, 2007). There is an 
ongoing interest to validate or to refute the immunoediting hypothesis, in relevant 
cancer models and in clinical pathologies. 
 
 
 
 
 
Figure  3:  Cancer  immunoediting  (adapted  from  Swann  and  Smyth,  2007).  Cancer 
immunoediting  is  a  process  divided  into  three  phases.  The  first  one,  named  elimination, 
corresponds  to  cancer  immune  surveillance.  During  the  equilibrium  phase,  immune  cells  and 
tumour  cells  are  temporary  in  dynamic  equilibrium  and  tumour  cells  continue  to  evolve, 
accumulating  genetic  changes.  Resistant  tumour  cell  variants  are  also  selected.  In  the  escape 
phase,  immune  response  fails  to  completely  eliminate  the  tumour  and  this  results  in  cancer 
progression. 
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Referring in particular to the central nervous system, our understanding of 
the interaction between immune system and tumour is not so clear; information is 
frequently extrapolated from other tissues which are indeed different from brain 
(Walker et al., 2002). It is well-known that immune reactions happening in the 
brain are specialised and unique (see the 1.3.1.) and further investigations are 
needed in order to completely understand them.  
 
1.3. IMMUNOLOGY OF THE CENTRAL NERVOUS SYSTEM 
 
1.3.1. The brain: an immunologically specialised site 
 
For many decades, the CNS has been believed to be an immunologically 
inert site completely separated from the peripheral immune system. It has been 
defined as an “immunologically privileged” site. Initially, in fact, it was observed 
that foreign tissue grafts survive for more prolonged periods when placed within 
the parenchyma of the brain compared with being placed under the skin (Carson 
et al., 2006). Accordingly, the presence of the BBB, the regulation of the cell 
trafficking  through  it,  the  lack  of  conventional  lymphatics,  many  local 
immunosuppressive factors and the absence of resident dendritic cells (DCs) have 
given support to the hypothesis that the brain is an immunologically inert site 
(Carson  et  al.,  2006;  Grauer  et  al.,  2009).  The  BBB  consists  of  specialised 
cerebrovascular endothelium, basement membrane, pericytes and astrocytes. The 
BBB  endothelium  has  tight  junctions,  low  pinocytotic  activity  and  lacks  of 
transendothelial fenestrations. Primarily, it has been presumed to limit movement 
of leucocytes and solutes from blood to CNS (Carson et al., 2006). Besides the 
physical restrictions described, it has to be taken in consideration the fact that the 
brain is an essential organ for survival and that has to be protected by pathogens; 
even  so,  it  cannot  tolerate  volume  increase  after  an  inflammatory  cellular 
accumulation, because the skull lacks elasticity (Carson et al., 2006). In addition, 
inflammatory  reactions  have  to  be  kept  under  control  in  order  to  avoid  their 
potential capacity to damage neurons (Carson et al., 2006; Walker et al., 2009). 
Diseases  such  as  multiple  sclerosis  (MS)  and  experimental  autoimmune 
encephalitis (EAE), multiple sclerosis model in animals, provide strong evidence 
that  immune  cells  can  act  in  the  brain  (Okada  et  al.,  2009).  Moreover,  the 
documentation  of  neuroinflammation  in  diverse  CNS  disorders  has  led  to  the 
conclusion  that  the  CNS  cannot  be  considered  an  immunologically  inert,  but 
rather an “immunologically specialised” site.  
With respect to brain and glioma, there is much evidence which proves an 
interaction between immune system and tumour (Walker et al., 2009; Okada et al., 20 
 
2009; Grauer et al., 2009). It should be noted that the BBB may be compromised 
in glioma patients and this can affect immune cells migration: permeability is 
higher due to increased fenestrations and due to the diminished number of BBB-
associated pericytes (Okada et al., 2009). But leukocyte entry into the CNS is 
generally  not  absolutely  dependent  on  breakdown  of  BBB  integrity.  Tissue-
selective  trafficking  of  leucocytes  is  mediated  by  unique  combination  and 
sequential  interactions  of  adhesion  molecules  and  chemokines  (Kunkel  and 
Butcher,  2002).  What  is  unique  to  the  CNS  is  the  specific  combination  of 
molecules and receptors used. The translocation of leucocytes occurs by the multi-
step model, clearly described in Kunkel and Butcher (2002). This model consists 
of a first process called rolling in which blood leucocytes interacting transiently 
and reversibly with the vascular endothelium. The second step is the activation of 
leucocytes  which,  after  their  biding  to  activation  factors  on  the  endothelium 
surface,  express  integrins.  During  the  following  process  named  adhesion, 
leucocytes reversibly arrest and adhere on vascular endothelium. The final step is 
the transmigration across the endothelium, directed by chemokine gradients. 
 
1.3.2. Brain tumour innate immunity 
 
The immune system is based on two distinct types of responses: innate 
immunity and adaptive immunity. Innate immunity provides the first defence of 
our organism against pathogens; it involves recognition of pathogens by receptors 
encoded  by  conventional  genes,  followed  by  activation  of  destructive  effector 
mechanisms.  The  cells  that  orchestrate  the  innate  immune  response  are 
monocytes,  macrophages,  granulocytes  (eosinophils,  basophils,  neutrophils  and 
mast  cells),  natural  killer  (NK)  cells  and  DCs.  Also  serum  proteins  of  the 
complement system participate in immune innate defence (Parham, The immune 
system, 2009).  
Adaptive immunity forms the second line of defence and is constituted by 
B and T cells. It acts in a highly specific way but the receptors are not necessarily 
pathogen-specific. They are characterised by infinite diversity, because encoded 
by  genes  which  undergo  somatic  recombination.  During  an  infection,  a  small 
subset  of  lymphocytes  specific  for  the  pathogen  is  selected  and  expanded. 
Adaptive immunity can also provide long-term immunological memory (Parham, 
The immune system, 2009). The interaction between immune cells of the innate 
immune system and immune cells of the adaptive immune system is determinant 
for  mounting  an  effective  immune  response.  As  seen  in  section  1.3.1.,  the 
distinctive  conditions  imposed  by  the  CNS  influence  the  anti-tumour  immune 
response happening in the brain. 21 
 
Microglia,  glial  cells  that  are  resident  macrophages  in  the  CNS,  are 
considered the first cells which respond to a variety of stress signals in the brain 
(Okada et al., 2009). In common with the other cells of the innate immune system, 
they  can  detect  pathogen-associated  molecular  patterns  (PAMPs)  by  means  of 
pathogen-recognition receptors (PPRs) that include the toll-like receptors (TLRs) 
(Walker  et  al.,  2009).  In  glioma,  resident  microglia  are  difficult  to  be  clearly 
distinguished  from  glioma-infiltrated  macrophages  (GIMs)  apart  from  by  flow 
cytometry.  The  GIMs  express  raised  levels  of  TLRs.  GIMs  are  the  largest 
subpopulation infiltrating glioma, however, differently to microglia, they do not 
appear  to  be  stimulated  to  produce  pro-inflammatory  cytokines  (Okada  et  al., 
2009), such as nitric oxide (NO) and tumour necrosis factor (TNF)-α (Prins and 
Liau, 2004). Both microglia and GIMs are phagocytic cells of myeloid origin with 
capacity of presenting antigen, but their ability of doing this is much lower than 
DCs  (Grauer  et  al.,  2009).  NK  cells  can  mediate  cytolysis  of  infected  or 
transformed cells and secrete INF-γ. In order to induce cytolysis, they require the 
presence of an activating signal, for example given by the expression of stress-
induced proteins by tumour cells, and simultaneously, the absence of an inhibitory 
signal  (reviewed  in  Walker  et  al.,  2009).  In  fact,  although  all  nucleated  cells 
normally express major histocompatibility complex (MHC) class I, transformed or 
virus-infected cells often down-regulate the classical MHC class I expression in 
an effort to avoid recognition by CD8
+ cytotoxic T lymphocytes (CTLs). NK cells 
can  recognise  and  kill  cells  which  do  not  present  MHC  class  I  (reviewed  in 
Walker et al., 2009). Actually, little is known about the potential impact of NK 
cells on human glioma (Walker et al., 2009). Also the role of granulocytes in the 
contest of glioma is not well-characterised in the literature. 
Another important cellular component of innate immunity is the dendritic 
cell. DCs are professional antigen-presenting cells (APC) and can activate naïve T 
cells  and induce their differentiation into T-effector cells.  Hence, their role in 
inducing adaptive immunity is very important. They are present in virtually all 
tissues and organs and they continuously monitor their environment. Moreover, 
they can be recruited to the tumour site from the periphery (Grauer et al., 2009). 
Two different subtypes of DCs exist: plasmacytoid and conventional DCs. The 
conventional  DCs  can  further  be  divided  in  migratory  and  lymphoid-tissue-
resident.  DCs,  after  the  capture  of  the  pathogen  or  antigen  and  activation  via 
PPRs,  undergo a process  named maturation and present  the processed  antigen 
(Ag) to the T cells in secondary lymphoid organs, using MHC class II and/or 
MHC  class  I.  Co-stimulatory  molecules,  such  as  members  of  the  B7  family, 
highly expressed by DCs, are needed to obtain full activation of naïve T cells 
(Walker et al., 2009). Focusing on glioma, the process of presenting tumoural 22 
 
antigen  has  been  formerly  hypothesized  to  happen  through  different  possible 
mechanisms: (1) after the uptaken of the Ag, DCs migrate to the cervical lymph 
node (cLN) and therein presents the Ag to the T cells; (2) Ag itself drains to cLN 
where it is taken up by DCs and processed; (3) tumoural cells that express Ag 
may  directly  drain  to  cLN  and  present  their  own  Ag.  The  first  hypothesis  is 
currently supported by several lines of evidence (Okada et al., 2009).  
 
1.3.3. Brain tumour adaptive immunity 
 
The cells that orchestrate adaptive immune responses are T cells and B 
cells.  Both  of  them  are  bone  marrow-derived  cells.  They  can  recognise  their 
cognate antigen through their specific receptor: T cell receptor (TCR) and B cell 
receptor (BCR). In particular, the portion of the antigen recognised by the T cell 
receptors is called the epitope, which derives from proteolytic cleavage (Parham, 
The immune system, 2009).  
Concerning B cells,  when cognate antigen binds to  their receptor, they 
proliferate  and  differentiate  into  plasma  cells,  which  secrete  high  level  of 
antibodies specific to the precise antigen encountered. Five different classes of 
antibodies  exist:  IgG,  IgA,  IgM,  IgD  and  IgE.  They  are  involved  in  several 
immune reactions, such as neutralisation and opsonisation, and they constitute the 
humoral arm of immunity (Parham, The immune system, 2009). In this section, 
the  attention  is  focused  on  T  cells  rather  than  on  B  cells,  because  the  B 
lymphocytes are probably not a major component of spontaneous immunity to 
brain tumours (Walker et al., 2009). In fact, B cells poorly infiltrate brain tumours 
and in addition, the capacity of antibodies to enter the brain is limited. 
Immature  T  cells  are  selected  in  the  thymus  to  recognise  self-MHC 
molecules (positive selection) and for the absence of autoreactivity against self-
antigens (negative selection). This process makes the immune system tolerant of 
self. In the context of self tolerance, a key role is played by the transcriptional 
factor  called  autoimmune  regulator  (AIRE),  which  facilitates  expression  of 
different tissue-specific genes by a subpopulation of epithelial cells in the medulla 
of the thymus. The phenomenon of tolerance is not limited to central (i.e. thymic) 
tolerance; autoreactive cells which escape deletion by central tolerance can be 
induced  to  become  anergic  or  can  be  suppressed  by  regulatory  T  cells  in  the 
periphery. Autoimmune diseases are generally caused by defects in self tolerance 
which result in autoreactive inflammation (Parham, The immune system, 2009). 
Immature T cells in the thymus express both CD4 and CD8 co-receptors. 
After maturation, they become single-positive CD4
+ or CD8
+ T cells. CD8
+ T 
cells generally recognise epitopes of endogenous origin, presented on MHC class 23 
 
I. CD4
+ T cells recognise epitopes derive from exogenous sources, presented on 
MHC class II. 
CD8
+ T cells recognise cognate peptide and the specific target cell if it 
expresses  appropriate  MHC  class  I.  They  can  adopt  different  cytotoxic 
mechanisms to induce apoptosis in their target cells. Cytotoxicity can derive from 
the contents of cytotoxic granules, released by exocytosis in the immunological 
synapse formed between the CTL and the target cell. The granule contents include 
perforin,  granulysin and granzymes (Parham, The immune system, 2009). The 
hypothesis that perforin is inserted into the target-cell membrane and creates pores 
through which granzymes can penetrate the cell has recently been debated in the 
literature. However, perforin is necessary to mediate the release of granzymes in 
the  cell.  Granzymes  trigger  apoptosis  of  target  cells  via  the  activation  of  the 
caspase proteolityc cascade or via caspase-indipendent mechanisms. CTLs  can 
also secrete TNF and lymphotoxins (LTs); they can also induce apoptosis of the 
target  cell  through  Fas  Ligand  (FasL)  binding  (Parham,  The  immune  system, 
2009).  After  antigen  presentation  in  the  cLN,  CD8  T  cells  undergo  clonal 
expansion.  Using  orthotopically  implanted  glioma  mice  models,  it  was 
demonstrated that CD8 T cell proliferation happens in superficial and deep cLNs 
and in lumbar lymph nodes (LNs), and it is associated with a rapid up-regulation 
of  the  integrin  heterodimer  α4β1,  very  relevant  for  the  brain  tropism  of  the 
activated T cells (Calzascia et al., 2005). Moreover, this study demonstrated that 
the imprinting of T cells depends on the site in which the antigen is captured, 
rather than the particular LN in which T cell proliferation occurs (Calzascia et al., 
2005). When CD8 T cells reach the tumour site, they further differentiate in the 
brain, exhibiting enhanced INF-γ and Granzyme B expression and induction of 
αEβ7 integrin expression that facilitates T cell retention in the brain (Masson et al., 
2007).  INF-γ,  a  type  II  interferon,  activates  macrophages  and  increases  the 
processing and presentation of antigens (Pharam, The immune system).  
Naïve CD4
+ T-cells can differentiate, depending upon the stimulus, into T-
helper type 1 (Th1), T-helper type 2 (Th2), Th17 cells or regulatory T cells (Treg 
cells).  CD4  T  cells  are  called  “helper  cells”  when  they  secrete  a  variety  of 
cytokines  that  enhance  the  function  of  other  cells  (Prins  and  Liau,  2004). 
Generally,  CD4
+  T  cells  can  help  B  cells  make  antibodies,  they  induce 
macrophages  to  develop  enhanced  microbicidal  activity,  and  they  recruit 
neutrophils, eosinophils and basophils to sites of infection (Parham, The immune 
system, 2009). Defining the role of CD4
+ T cells in brain tumour immunity is 
complicated, due to the fact that they can either manifest pro- or anti- tumour 
effects. Besides, very few glioma antigens recognised by CD4
+ T cells have been 
identified (Walker et al., 2009). 24 
 
1.3.4. Tumour immune escape 
 
Despite  the  observation  that  immune  cells  can  infiltrate  the  tumour  in 
glioma patients  (see  section  1.3.1.), the role of the immune system  in  tumour 
progression  is  still  debated.  In  section  1.2.,  the  theory  of  “immunoediting”  is 
explained; according to this concept, the tumour can overwhelm immune response 
due to selection of resistant tumour cell variants. The escape of the tumour from 
the  immune  system  response  is  usually  defined  as  tumour  immune  escape. 
Tumour escape permits the progression of the tumour to advanced stages (Cao, 
2009), thus understanding the mechanism is a major challenge for cancer research. 
Glioma  immune  escape  mechanisms  can  be  divided  into  two  different 
groups: passive and active. The passive mechanisms are represented by intrinsic 
properties  of  glioma  cells.  Indeed,  glioma  may  attempt  to  passively  escape 
immune detection by downregulation of MHC expression; furthermore, areas of 
hypoxia represent a hostile microenvironment for immune cells (Walker et al., 
2009).  The  immunosuppression  actively  elicited  by  glioma  concerns  soluble 
factors, cell surface molecules and immunosuppressive cells (Walker et al., 2009; 
Grauer  et  al.,  2009;  Okada  et  al.,  2009).  As  a  consequence,  in  the  tumour 
microenvironment  the  normal  function  of  immune  effector  cells  is  profoundly 
suppressed (Grauer et al., 2009; Tran Thang et al., 2010) and the presence of 
immunostimulatory molecules such as interleukin (IL)-12 and INF-γ is lacking 
(Grauer et al., 2009; Tran Thang et al., 2010). The glioma microenvironment is 
composed  of  tumour  cells,  endothelial  cells,  intermingling  glia,  neurons, 
extracellular matrix fibers, soluble mediators and a variety of leukocyte subsets 
(Okada et al., 2009). 
One of the most extensively studied glioma-derived immunosuppressive 
factors is Transforming Growth Factor (TGF)-β2, originally called glioblastoma 
cell-derived T-cell suppressor factor (Walker et al., 2002). TGF-β2 is an isoform 
of TGF-β in mammals; the isoforms TGF-β1, 3 and 4 are differentially expressed. 
TGF-β2 has multiple and complex effects; in particular it inhibits maturation and 
antigen  presentation  by  DCs  or  other  APC  (Okada  et  al.,  2009)  and  also 
suppresses  NK  and  T-cell  proliferation  (Walker  et  al.,  2009).  It  has  been 
demonstrated that TGF-β2 is produced by glioma cells and by glioblastoma in 
vivo (reviewed in Walker et al., 2009). All these characteristics make TGF-β2 an 
attractive target for novel therapeutic approaches and the most advanced in the 
clinical application is the use of an antisense oligonucleotide (Grauer et al., 2009). 
Other  immunosuppressive  soluble  glioma  origin-factors  are  gangliosides, 
prostaglandin  E2  and  IL-10  (Walker  et  al.,  2002).  Gangliosides  (GANGs)  are 
sialic  acid-containing  glycosphingolipids  present  in  human  plasma  (Dix  et  al., 25 
 
1999). GANGs can modulate lymphocytes responsiveness; it can be speculated 
that immunosuppression by GANGs might account for some of the dysfunctions 
observed  in  glioma  patients  (Dix  et  al.,  1999).  Prostaglandin  E2  (PGE2)  is  a 
product  of  arachadonic  acid  metabolism  and  it  is  produced  at  the  sites  of 
inflammation or tissue damage where it can enhance the vascular permeability 
(Dix et al., 1999). The role of PGE2 in glioma tolerance has not been clarified yet 
and further characterizations are needed. In fact, PGE2 can be associated with the 
suppression of T-cell function and is synthesized by glioma (Dix et al., 1999). 
However, the concentration of PGE2 observed in glioma-cell supernatant is not 
comparable to the concentration required to inhibit T-cell proliferation (reviewed 
in Okada et al., 2009). Glioma cells synthesize and secrete IL-10; mRNA levels of 
IL-10 are higher in high-grade astrocytoma rather than in low-grade astrocytoma 
(reviewed in Dix et al., 1999). IL-10 also has been shown to reduce the antigen 
presentation capacity of monocytes by down regulating MHC class II expression 
(Dix et al., 1999). 
With respect to the cell surface molecules expressed on glioma cells, FasL 
has been proposed to contribute to tumour immune escape. FasL belongs to the 
Tumour Necrosis Factor (TNF) family and it is expressed on glioma cells in vivo 
and in vitro (Walker et al., 2009). Its receptor is Fas. The interaction of the latter, 
expressed  on  Fas-positive  cells,  with  FasL,  leads  to  a  complex  cascade  of 
intracellular  events  ending  with  cell  apoptosis  (Okada  et  al.,  2009).  The 
expression of FasL on glioma cells can induce apoptosis of Fas-positive T-cells 
that infiltrate into the tumour tissue (Okada et al., 2009). The microenvironment 
can influence the consequences of FasL expression by tumour cells: it has been 
hypothesized that tumours expressing both FasL and TGF-β2 may be particularly 
advantaged to overwhelm the action of CD8 T-cells (Walker et al., 2002). Other 
two  cell  surface  molecules  proposed  to  facilitate  glioma  immune  escape  are 
CD70, a member of the TNF family, and Human Leukocyte antigen (HLA)-G, a 
non classical MHC class I molecule (Okada et al., 2009). 
Immunosuppressive  cells  play  an  important  physiological  role  in 
regulating autoimmunity and controlling inflammation. In some cases, they can be 
recruited  or  activated  by  factors  produced  by  tumour  cells,  promoting  tumour 
escape (Walker et al., 2009). Treg cells represent a subpopulation of CD4 T-cells 
and are the most studied immunosuppressive cells in cancer research (Cao, 2009). 
A  large  numbers  of  Treg  cells  have  been  found  either  in  circulation  or  in  the 
tumour micro-environment of patients with various cancers, such as lung, breast, 
gastric, colorectal cancer and melanoma (reviewed in Cao, 2009). Also in patients 
with malignant glioma, the Treg fraction is greatly increased (Fecci et al., 2006). 
Two populations of Treg exist: natural Treg (nTreg) are produced in the thymus, 26 
 
whereas induced Treg (iTreg) derive from CD4 naïve T cells which differentiate 
under the influence of certain cytokines, in particular IL-2 and TGF-β (Walker et 
al., 2009). nTreg normally migrate to the periphery and account for 10-15% of 
CD4
+  lymphocytes  (Cao,  2009).  Distinguishing  the  functions  of  these  two 
populations and their relative contribution to the comprehensive action of Treg in 
humans  and  in  experimental  animals  is  challenging  (Cao,  2009).  FoxP3
+  is  a 
useful Treg marker. It is a transcription factor and therefore it is inaccessible to 
antibodies in vivo, largely used for depletion in experimental studies with mouse 
models  (Walker  et  al.,  2009).  The  function  of  Treg  in  immune  homeostasis  is 
exemplified  by  the  immunodysregulation  polyendocrinopathy  enteropathy  X-
linked (IPEX) human disease. IPEX is caused by mutations in the gene FOXP3; 
as  a  result,  the  product  of  this  gene  is  non-functional  and  this  results  in 
autoimmunity and inflammation. The mouse genetic equivalent for this disease is 
the so-called Scurfy mouse. The impact of FOXP3
+ mutation either in humans or 
in  mice  underlines  the  critical  role  of  the  transcriptional  factor  Foxp3  in 
controlling autoimmune and immunopathologic responses (Walker et al., 2009). It 
is likely that Treg cells utilise multiple mechanisms to suppress protective tumour 
immunity. The first mechanism considered is the secretion of inhibitory cytokines, 
in particular IL-10, TGF-β and IL-35 (Cao et al., 2009). Diverse studies have been 
performed to better understand the role of these cytokines, either in vivo or in 
vitro. Previously in this section, the role of IL-10 and TGF-β, also produced by 
glioma cells, has been explained. IL-35 has been recently investigated in immune 
suppression. The role of this cytokine in Treg function in the tumour setting has not 
been reported (Cao, 2009) and human studies demonstrated that Treg cells do not 
express IL-35 constitutively (reviewed in Cao, 2009). A second mechanism of 
action of Treg cells is the use of perforin/granzyme-mediated cytotoxicity. This 
pathway is known to be utilized by CD8
+ T cells and NK cells to kill host cells 
infected  by  pathogens  or  transformed  tumour  cells.  In  addition  to  these  two 
mechanisms, Treg cells may also suppress immune responses by modulating APC. 
In  a  transgenic  EAE  model,  it  has  been  reported  that  the  presence  of  Treg 
attenuates the establishment of stable contacts between effector T cells and DCs 
during T cell priming in the lymph nodes (reviewed in Cao 2009). Another type of 
immunosuppressive cell which is considered to have a role in glioma escape is the 
myeloid  derived  suppressor  cell  (MDSC).  Also  mesenchymal  stem  cells,  a 
phenotypically  heterogeneous  cell  population,  are  immune  suppressive  cells. 
Normally, they have anti-inflammatory or anti-proliferative effects on immune 
cells, but they increase glioma proliferation (Walker et al., 2009). 
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Figure 4: Different mechanisms of glioma immune escape. Passive and active tumour immune 
escape mechanisms are shown in this figure. Glioma cell down regulates MHC class I molecules 
expression. Furthermore, FasL is present on cell surface. Hypoxia in tumour microenvironment 
contributes to suppress normal functions of immune cells. Glioma cell actively secretes soluble 
immunosuppressive factors (TGF-β, IL-10 and PGE2 are represented). Immunosuppressive Treg 
cells also play an important role in glioma immune escape. Their functions are briefly illustrated in 
the figure.  
 
 
1.3.5. Impaired immune function in glioma patients 
 
Immunosuppression is frequently associated with malignancy. In glioma 
patients,  although  the  tumour  remains  in  the  intracranial  compartment, 
immunosuppression  is  both  systemic  and  profound  (Fecci  et  al.,  2006).  As 
previously discussed, glioma can adopt different mechanisms to escape immune 
system  responses  and  to  influence  the  normal  activity  of  immune  cells. 
Proliferative  hyporesponsiveness  of  peripheral  blood  T  cells  in  response  to 
mitogen stimulation in vitro was shown in glioma patients (reviewed in Waziri, 
2010). The decrease in responsiveness is variable; tumour size and not location 
influences the observed amount of immunosuppression (Morford et al., 1997). 
Additionally,  reduced  secretion  of  IL-2  and  the  presence  of  defective  IL-2 
receptor  (IL-2R)  on  T  cells  characterised  glioma  patients  (Dix  et  al.,  1999). 
Specifically, proliferative dysfunction is manifested within the CD4
+ T-cell subset 
(reviewed in Fecci et al., 2006). T cell abnormalities are temporarily reversed with 
tumour resection and return with tumour recurrence, potentially confirming an 
association between tumour and the suppressive phenotype (reviewed in Waziri, 
2010). Severe T cell lymphopenia is another frequently observed defect in patients 28 
 
bearing glioma (reviewed in Dix et al., 1999). Lymphopenia involves  T cells, 
whereas  B  cells  percentage  and  absolute  number  in  the  peripheral  blood  of 
patients are normal (reviewed in Dix et al., 1999). With respect to the percentages 
of  T  cells,  the  number  of  CD4
+  T  cells  obtained  from  patients  is  reduced  in 
comparison to the number of CD8
+ T cells. The normal CD4/CD8 T cells ratio is 
consequently shifted, resulting closer to 1, rather than the usual 2:1 (reviewed in 
Waziri,  2010).  Treg  frequently  represents  an  important  fraction  in  the  CD4 
compartment (Fecci et al., 2006). Furthermore, cytokine production is aberrant. 
Th2 cytokine production in glioma patients is usually at higher levels than the 
production of Th1 cytokines (Fecci et al., 2006). Th1 CD4 T cells mediate immune 
responses  against  intracellular  pathogens,  and  they  produce  INF-γ,  IL-2  and 
lymphotoxin α (LTα). Th2 cells mediate immune responses against parasites and 
are involved in allergy and asthma; they secrete IL-4, IL-5, IL-13, IL-25 and IL-
10 (Parham, The immune system, 2009). Another hallmark of glioma patients is 
diminished  delayed  type  hypersensitivity  (Walker  et  al.,  2002).  Moreover,  in 
glioma patients Treg negatively regulates cellular immunity. In peripheral blood, 
Treg fraction is increased and it correlates with T cell proliferative defects. 
Although the mass of information on immune function in patients strongly 
supports the idea of immune impairment, there are certain issues that remain. In 
general, the studies on glioma patients peripheral immune status did not report 
and did not take into account the treatment they were receiving, which interferes 
with immune cell functionality and viability. Furthermore, all data refer to later 
stages of the disease, corresponding to the symptomatic phase when patients are 
studied,  and  give  no  information  on  the  origin  of  glioma  systemic 
immunosuppression.  Many  tests  are  in  vitro,  and  thus  do  not  necessary 
recapitulate  in  vivo  immune  function.  Additionally,  the  studies  are  limited  to 
blood samples, because tissues such as spleen or lymphoid tissues are not readily 
available in patients.  
 
1.3.6. Glioma antigens and immunotherapy 
 
Immunotherapy aims to induce antitumour immune response leading to the 
eradication  of  malignant  cells  (Grauer  et  al.,  2009).  The  understanding  of  the 
particular circumstances required and the identification of the immune cells that 
are able to perform it are essential in developing efficient strategies for cancer 
therapy (Walker et al., 2009).  
In order to obtain efficient and safe immunotherapy, immune cells have to 
identify correctly and specifically tumour-associated antigens (TAAs) (Prins et 
al.,  2004).  Evidently,  an  ideal  target  for  immunotherapy  is  an  antigen  that  is 29 
 
specifically  and  stably  expressed  by  the  tumour  and  absent  in  normal  tissues 
(Grauer  et  al.,  2009).  Importantly,  TAAs  used  in  immunotherapy  have  to  be 
immunogens,  namely  they  induce  immune  responses.  Advances  in  molecular 
genetics and immunology have enabled the identification of several human glioma 
antigens (Prins et al., 2004). One of the most intensely studied tumour-specific 
antigens expressed by human glioma is EGFRvIII (Kanu et al., 2009), expression 
of which is derived from the oncogenic transformation process. Three principal 
diverse  approaches  of immunotherapy  can be investigated: passive, active and 
adoptive (Grauer et al., 2009).  
Passive  immunotherapy  consists  of  using  a  variety  of  effective  molecules, 
including  monoclonal  antibodies  (Okada  et  al.,  2009).  Specific  monoclonal 
antibodies can be conjugated with radionucleotides and recognise TAAs (Okada 
et  al.,  2009).  Notably,  with  respect  to  brain  tumour,  antibodies  have  the 
disadvantage to be quite limited in penetrating into the tumour tissue (Grauer et 
al., 2009).  
Active immunotherapy, which can also be defined as tumour vaccination, 
is an active immunization of patients with the aim to induce potent antitumour 
responses in vivo. In order to induce specific T cell responses, peptide vaccines or 
recombinant  bacterial  or viral  vaccines can be  used (Walker et  al.,  2009). To 
obtain reproducible, effective, long lasting anti-tumour response, the utilisation of 
adjuvants is required. Adjuvants enhance the immune response by prolonging the 
time of exposure to antigen and by increasing the activity of APCs (Walker et al., 
2009). 
Adoptive immunotherapy consists of adoptive transfer of effector T cells 
harvested from patients, activated and expanded in vitro. Using this technique, 
optimal conditions for the culture and amplification of these cells is provided, in 
absence of tumour-derived immunosuppressive factors (Grauer et al., 2009).  
 
1.4. MOUSE MODELS TO STUDY BRAIN TUMOURS 
 
1.4.1. Animal models in tumour immunology 
 
Brain tumour models, reflecting different characteristics of human glioma, 
are relevant for the evaluation of new potential therapies. They also represent an 
essential tool for understanding complex molecular pathways occurring in brain 
tumours. The features of a robust glioma model include (1) tumours arise from 
glial cells, (2) similar molecular pathogenesis and similar molecular profiles to 
human  glioma,  (3)  responsiveness  to  known  therapeutics,  (4)  predictable 
development of tumours at a high incidence (Munoz et al., 2009). Importantly, 30 
 
focusing on glioma progression and its interactions with the immune system, the 
use of models allows the study of the tumour even at early stages. In contrast, 
patients  cannot  be  studied  until  the  clinical  diagnosis,  which  is  usually  made 
during the later stages of the disease. Furthermore, there are several problems and 
limitations in studying the immunology of glioma in patients, because they are 
usually undergoing a specific treatment which interferes with immune responses. 
Also tissues such as human brain or lymphoid tissue are not readily available. 
 
1.4.2. Murine models of glioma 
 
Different  kinds  of  murine  models  can  be  utilised  in  brain  tumour 
immunology;  in  particular,  grafted  models  and  genetically  engineered  mouse 
models  (GEM)  are  described  in  this  section.  Human  glioma  xenografted  into 
immunodeficient  mice,  although  commonly  used,  will  not  be  considered  here 
because they exclude the study of physiological immune interactions. In contrast, 
in  fully  syngeneic  grafted  mouse  models  and  in  GEMs,  interactions  between 
tumour and immune system can be studied. The most appropriate model to use 
has to be chosen according to the questions the specific research addresses.  
In  grafted  models,  cell  lines  from  individuals  of  the  same  strain  are 
implanted by intra-cerebral injection. This kind of model has predictable features 
and kinetics, but it does not mimic tumour heterogeneity, the hallmark feature in 
glioma.  In  grafted  models,  tumour  is  usually  homogeneous  and  has  not 
accumulated  multiple  genetic  defects  as  happens  in  humans.  Furthermore,  the 
implantation  of  tumour  is  an  artificial  process  and  influences  several  in  vivo 
parameters. In fact, the injection itself can affect the integrity of the BBB and 
immune responses may not occur as gradually as in the spontaneous pathology. 
Genetically  engineered  glioma  mouse  models  have  been  created 
introducing some of the same genetic abnormalities seen in humans. They can be 
generated  by  introducing  germ-line  or  somatic  modifications  (de  Vries  et  al., 
2009). Germ-line models, in particular, give the possibility to obtain spontaneous 
tumours.  They  are  based  on  loss  or  increased  expression  of  relevant  genes 
implicated  in  human  glioma  pathogenesis  and  they  also  provide  a  unique 
opportunity  to  examine  pathological  alterations  associated  with  tumour 
development (Shannon et al., 2005). In these models the integrity of brain and of 
the BBB is only disrupted subsequent to tumorigenesis.  
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1.4.3. RasB8 glioma model  
 
GFAP-V
12  HA-ras  B8  (referred  to  hereafter  as  RasB8)  is  a  germ-line 
genetically engineered astrocytoma mouse model. In this thesis, we utilised two 
different  genetic  backgrounds  of  the  strain:  RasB8-CD1  and  RasB8-129  (see 
section 2.1.1.). RasB8 model is characterised by the presence of the transgene V
12 
HA-ras:IRES-LacZ,  the  expression  of  which  is  regulated  by  the  astrocytes-
specific glial fibrillary acid protein (GFAP) promoter (Ding et al., 2001).  
 
 
 
 
 
 
Figure  5:  The  transgenic  construct  in  RasB8  mice  (adapted  from  Ding  et  al.,  2001).  The 
specific GFAP promoter drives the expression of 12V HA-ras gene. IRES-LacZ (which encodes 
for β-galactoside protein) is also under the control of the same promoter. 
 
 
The technique to obtain RasB8 mice used the transfection of a retrovirus, 
which carries the gene of interest and a selection marker, into cultured mouse 
embryonic stem (ES) cells. After positive selection, cells undergo aggregation and 
are transferred to a pseudo-pregnant female mouse to create chimeric embryos. 
The chimeric mice are then bred to normal mice and mice which incorporated the 
transgene in their germ-line generate transgenic offspring (Munoz et al., 2009). 
The  overexpression  of  V
12  HA-ras  gene,  although  not  a  primary  molecular 
aberration of human astrocytoma, can initiate the sequence of genetic events that 
lead to the development of astrocytoma in mice (Munoz et al., 2009). It was also 
demonstrated that astrocytoma formation is dependent on V
12 HA-ras gene dosage 
(Ding  et  al.,  2001).  There  is  evidence  that  RasB8  mice  exhibit  similarities  in 
pathological and molecular progression features to human astrocytoma (Shannon 
et al., 2005; Ding et al., 2001). In fact, the mouse astrocytoma is composed of 
GFAP-positive,  highly  mitotic,  pleomorphic  and  infiltrative  astrocytes,  also 
associated with increased vascularity and necrosis (Ding et al., 2001). Besides, 
several  genetic  alterations  associated  with  human  low-  and  high-  grade 
astrocytoma  are  noted  in  this  mouse  model.  They  present  gain-of-function 
mutations as evidenced by increased expression of EGFR and VEGFR, as well as 32 
 
loss-of-function  alterations,  including  changes  in  Tp53  expression  or  TP53 
mutations (Shannon et al., 2005). 
The development and the progression of astrocytoma in RasB8 model are 
heterogeneous in frequency, latency, growth and location; this heterogeneity is 
reminiscent  of  human  tumour  heterogeneity.  RasB8  tumour  progression  was 
examined by Shannon and colleagues  (2005). At  birth  RasB8 transgenic mice 
appear normal and astrocytes are not transformed. Glial hyperplasia is the first 
distinguishing feature in 3-week-old mice. From 3 to 8 weeks, the incidence of 
low-grade  astrocytoma  progressively  increased.  80%  of  12-week-old  mice 
harbour low- or high- grade astrocytoma, 50% of mice die by 4 months. 
 
 
 
 
 
Figure 6: Astrocytoma progression in RasB8 mice (adapted from Shannon et al., 2005). The 
development of the pathology is analysed at different time points. Glial hyperplasia is observed in 
the majority of the 4 week-old mice; low-grade astrocytoma progression is gradual. High-grade 
astrocytoma is found in 30% of the 12 week-old mice.  
 
 
1.5. AIM OF THE PROJECT 
 
Glioma  is  one  of  the  most  aggressive  and  deadliest  brain  tumours. 
Different new therapeutic approaches have led to an improvement in survival, but 
prognosis still remains poor. This study focuses on glioma immunology. Different 
studies demonstrated immunosuppression in patients, both at the local and at the 
peripheral level. However, as discussed, whether this occurs at early stages of 
disease,  and  whether  it  is  independent  of  treatment  status  is  unclear.  In  this 
project, we used a spontaneous astrocytoma mouse model, RasB8, in order to 
investigate peripheral immune status.  
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Three principal issues were addressed in this thesis: 
 
1) Do RasB8 mice display an altered peripheral immune phenotype and is this 
reflected in the CD4/CD8 T cell ratio?  
 
2) Do RasB8 T cells show impaired functional responses once removed from the 
potentially immunosuppressive in vivo environment (i.e. in vitro)? 
 
3)  Are  RasB8  T  cells  able  to  exhibit  functional  responses  in  vivo,  after 
vaccination?  
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2. MATERIALS AND METHODS 
 
2.1. MICE 
 
2.1.1. Strains and breeding  
 
Hemizygous  transgenic  GFAP-V
12  HA-ras  B8  (RasB8)  mice  (kindly 
supplied by Dr A. Guha), expressing a single allele of oncogenic V12 HA-ras, 
were used. The strain was previously described (section 1.4.3). Other two mouse 
model  strains  used  in  this  study  are  129  S2/SvPasCr1  (MHC  haplotype  H2
b) 
inbred strain (Charles Rivers) and C57BL/6 (MHC haplotype H2
b) inbred strain 
(Charles Rivers). Also outbred mouse strain CD1 (Charles Rivers) was bred at our 
institution.  RasB8  mice  were  maintained  on  the  CD1  background  (hereafter 
RasB8-CD1); S2/SvPasCr1 mice were back-crossed with RasB8 mice and mice 
from seventh to tenth generation were utilised in this study. Both RasB8-CD1 and 
129  S2/SvPasCr1xRasB8  (hereafter  RasB8-129)  mice  were  screened  for  the 
presence  of  the  oncogene  V12  HA-ras.  Mice  were  sacrificed  by  isoflurane 
inhalation.  All  procedures  adopted  were  approved  by  the  Institutional  Ethical 
Committee and the Cantonal Veterinary Office (Suisse). 
RasB8-CD1  and  RasB8-129  mice  were  followed  weekly  for  the 
development of symptoms. They were considered ill when exhibit more than one 
of  the  following  symptoms:  loss  of  weight,  ruffled  fur,  debility,  irregular 
breathing, convulsions, difficulty of movement, hunched posture.  
 
2.1.2. Polymerase Chain Reaction: general principles 
 
The Polymerase Chain Reaction (PCR) is a molecular biology technique 
which  permits  the  amplification  of  a  precise  fragment  of  DNA  called  “target 
DNA” starting from DNA termed “template DNA”. The enzyme which catalyses 
this reaction is a thermostable DNA polymerase, isolated from the Gram- bacteria 
Thermus  aquaticus.  Oligonucleotides  complementary  to  the  sequences  which 
flank the target DNA are required as primers to specifically direct the polymerase 
to copy the sequence of interest. Primers provide a free 3'-hydroxyl group. In the 
reaction mix, deoxyribonucleotides (dNTPs) are also needed. PCR is based on 
thermal cycling and is divided in different stages: denaturation, annealing and 
extension.  Each  step  is  repeated  from  30  to  40  times.  In  the  first  stage,  the 
template DNA is denaturated by heating above 90°C. The two strands of DNA 
separate and the target DNA is made accessible. During the annealing stage the 
temperature is cooled to around 60°C. During this step, oligonucleotide primers 35 
 
hybridise  with  their  complementary  sites.  The  DNA  synthesis  step  is  termed 
extension.  During  this  stage,  polymerase  extends  the  target  sequences.  The 
temperature required for the extension corresponds to the optimum temperature of 
the enzyme used (commonly around 72°C). After one cycle of PCR, new strands 
are synthesised and they become templates during the next cycle of the reaction. 
In  this  way,  PCR  provides  an  exponential  increase  in  the  amount  of  DNA 
produced. Furthermore, all new strands have a precise length, because polymerase 
amplifies  the  target  DNA  and  the  regions  flanking  it.  After  the  reaction,  the 
amplified DNA fragments can be visualised on an agarose gel. The specificity of 
this  technique depends  on the design of the two oligonucleotide primers. The 
sensitivity of PCR is very high, foreign DNA contamination has to be avoided 
using dedicated equipment.  
 
2.1.3. Genotyping 
 
DNA extraction was performed on crude lysate of mice tails. After 5% 
isoflurane (Abbott, Baar, Switzerland) inhalation anaesthesia, 0.5 cm of tail was 
cut. DNA digestion was performed with 200 μl tail lysis reagent (PeqLab Direct 
PCR) containing 0.3 mg/ml proteinase K (Roche). A 55°C overnight incubation, a 
45 minutes 85°C final incubation were performed. Lysates were directly used for 
PCR reaction or stored at -20°C. PCR amplification used a forward primer located 
in  the  GFAP  promoter  (5'-ACTCCTTCATAAAGCCCTCG-3')  and  a  reverse 
primer  located  in  the  3'  region  of  the  HA-ras  cDNA  (5'-
CTCGAATTCTCAGGAGAGCACACACTT-3')  and  was  controlled  by  a  PCR 
amplification of β-actin, using the following primers (all primers from Sigma): 
forward  5'-GCCAACCGTGAAAAGATGAC-3'  and  reverse  5'-
GACCAGAGGCATACAGGGACAG-3'.  Primers  were  used  at  333  nM 
concentration. Both PCR were performed in the same 25 μl mix (12.5 μl REdTaq 
Ready Mix Sigma, 8.5 μl distillated H2O, primers, 2 μl template DNA). PCR of 
35 cycles with denaturation at 94°C for 1 minute, annealing at 61°C for 1 minute 
and extension at 72°C for 1 minute (and with initial denaturation at 94°C for 5 
minutes and final extension at 72°C for 5 minutes) was performed in GTC thermal 
cycler  (Cleaver  Scientific).  Amplified  DNA  fragments  were  loaded  on  a  1% 
agarose (Sigma) gel prepared in 100 ml TBE buffer 1x with 4 µl Sybrsafe (SYBR, 
safe DNA gel stain 10,000x concentrated in DMSO, Invitrogen). One hour DNA 
electrophoresis at 85 V in TBE 1x was performed. The SMARTLADDER SF 
(Eurogentec) marker ladder was used to determine the length of the fragments 
amplified.  
 36 
 
 
 
Figure 7: Example of DNA genotyping. In this figure, an example of PCR agarose gel used to 
discriminate transgenic RasB8 and non transgenic mice is shown. On the left of the picture, the 
molecular weight marker ladder is observed; band size displayed refers to base-pair (bp). The 
house keeping gene used is β-actin, corresponding to the 700 bp bands. It is present in all samples, 
with the exception of negative controls (first and last column), in which distillated water was 
added to PCR reaction mix, instead of DNA. 800 bp bands correspond to the transgene; hence, 
samples which show two bands are RasB8 transgenic mice. In non transgenic mice, only the β-
actin band is visible.  
 
 
2.2. FLOW CYTOMETRY 
 
2.2.1. General principles of immunofluorescence 
 
Immunofluorescence  is  a  technique  that  permits  to  visualise  cellular 
antigens by using fluorescent molecules (fluorochromes) conjugated to specific 
monoclonal antibodies. Fluorochromes, if excited at their excitation wavelength, 
are  able  to  emit  light  at  their  emission  wavelength.  Two  different  kinds  of 
immunofluorescence  staining  exist:  direct  and  indirect.  The  direct 
immunofluorescence  technique  uses  antibodies  directly  conjugated  to  a 
fluorochrome (primary antibody). The indirect technique uses one primary non-
labelled  antibody  and  a  second  antibody  conjugated  with  a  fluorochrome 
(secondary  antibody).  Indirect  immunofluorescence  can  also  utilise  a  tertiary 
fluorochrome-conjugated antibody if the secondary is not-labelled, or can adopt 
an antibody biotin-conjugated. For the latter case, streptavidin (SA)-conjugated 
fluorochrome is required.  
 
 
Antibody  Fluorochrome  Emission 
peak (nm) 
Clone  Company 
CD4  PE  575  GK 1.5  BD Bioscences 
CD4  APC/ Cy 7  774  GK 1.5  Biolegend 
CD8  APC  660  53-6.7  BD Bioscences 
CD8   APC/ Cy 7  774  53-6.7  BD Bioscences 
Ly-6C*  SA-PerCP/Cy5.5  690  HK 1.4  Biolegend 37 
 
CD11b   PE/ Cy 7  774  M1/70  BD Bioscences 
B220  APC  660  RA3-6B2  BD Bioscences 
CD44°  FITC  525  IM7  BD Bioscences 
CD62L   PE  575  Mel-14  ImmunoKontact 
INF-γ   PE/ Cy 7  774  XMG 1.2  Biolegend 
 
Table 2: Antibodies. In the table, antibodies  used  in this experimental  work  are  shown  with 
emission peak of their conjugated fluorochromes. (*) this antibody was biotinilated. All antibodies 
were from rat, except (°) from mouse. 
 
 
If the amount of antibody used is appropriate to saturate all antigenic sites 
on cells, the amount of the emission light is proportional to the number of target 
molecules stained. The correct antibody concentration is determinated by titration. 
As negative control, staining is performed with an antibody of the same isotype, 
but which is of irrelevant specificity. Usually, the staining with the isotype is 
compared to the staining with the antibody, to detect the real expression of the 
antigen of interest.  
 
 
Isotypes  Fluorochrome  Correspondent 
antibody 
Clone  Company 
IgG2b   PE  CD4  A95-1  BD Bioscences 
IgG2a   FITC  GR1  R 35-95  BD Bioscences 
IgG2a   APC  B220  RTK 2758  Biolegend 
IgG2a   APC/ Cy 7  CD8  10 797  BD Bioscences 
 IgG2c*°  SA-PerCP/Cy5.5  Ly-6C   RTK 4174  Biolegend 
IgG2b   PE/ Cy 7  CD11b  A95-1  BD bioscences 
IgG1   PE/ Cy 7  INF-γ  MOPC-21  BD bioscences 
 
Table 3: Isotypes. In the table, control isotypes used in this experimental work are displayed. The 
correspondent antibodies are also shown. (*) this antibody was biotinilated. All antibodies were 
from rat, except (°) from mouse. 
 
 
If  intracellular  staining  is  required,  it  is  performed  after  the  surface 
staining. For intracellular staining, cells are fixed and secretion of molecules such 
as interferon and chemokines is usually inhibited using monensin, an antibiotic 
which blocks intracellular protein transport. Importantly, cell permeabilization is 
required  to  permit  antibody  penetration  into  the  cells.  Antibodies  have  to  be 
prepared in permeabilization buffer to ensure the cells remains permeable. 
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2.2.2. Principles of flow cytometry 
 
Flow cytometry is a technique which detects several parameters of a cell 
population after immunofluorescence staining. In this experimental study, cells 
were analysed using Gallios
TM (Beckman Coulter) flow cytometer and results were 
processed  with  Flowjo  7.2.5  software  (Treestar  Inc.)  or  with  Kaluza  Flow 
Cytometry analysis 1.0 software (Beckman Coulter). 
Flow  cytometer  permits  to  measure  individual  cell  fluorescence  and  to 
acquire data from thousands of cells per second. The instrument is composed of 
different parts: fluidics, optics, electronics and computer. Samples are injected 
into a sheath flow and each cell is forced to pass through different laser beams 
that  have  passed  through  optical  filters.  Once  fluorochromes  are  excited,  the 
emission  light  is  direct  to  optical  detectors  (in  this  work,  named  FL).  The 
electronic  system  is  constituted  by  photomultiplier  tubes  that  convert  the 
incidence light into electronic pulses. The signal is finally amplified and digitized 
for  computer  analysis.  Flow  cytometers  can  be  equipped  with  more  than  two 
lasers; consequently, several fluorochromes are used at the same time to obtain 
diverse cell parameters from one sample. Importantly, most fluorochromes do not 
have a tight emission spectrum, thus compensation is needed to correct overlaps 
in  the  emission  spectra.  Compensation  is  usually  established  by  software 
programs. 
Data acquired by the flow cytometer are displayed in different types of 
graph,  which  can  show  one  or  two  parameters  at  the  same  time.  Usually,  a 
logarithmic scale is adopted and the unit of measure corresponds to the voltage 
generated in the photomultiplier tube by light emitted from excited cells. Graphs 
which  show  two  parameters  simultaneously  are  utilised  to  identify  cell 
subpopulations. In particular, in dot plot graphs, each dot plot represents a single 
cell.  To  initially  identify  the  cell  subpopulation  investigated  and  to  gate  one 
specific subset, the dot plot with forward scatter (FS) on x-axis and side scatter 
(SS) on  y-axis  is visualised.  FS correlates  with size of cells, SS with cellular 
granularity. Double-positive cell dots are situated in the upper right region of the 
plot, whereas double negative dots on the lower left region. Single positive for the 
parameter on x-axis are situated in lower right region, for the parameter on y-axis 
in the upper left region. Other kind of two parameter graphs can be used, such as 
Density,  Pseudocolour,  Zebra  and  Contour  plots  according  to  the  analysis  to 
perform. Another type of graph is histogram which measures only one parameter 
on x-axis and the respective count of cells on y-axis. Stainings with the same 
fluorochrome from the same or from different samples can be overlayed on this 
kind of graph.  39 
 
 
 
 
Figure 8: Dot plot and histogram. A) Example of dot plot graph in which SS and FS scatter is 
shown. Gating on different populations is possible, according to size and granularity. B) and C) 
Examples of histogram. Two distinct populations are represented in both graphs: the population 
with higher fluorescence is CD8 positive and it is represented by the peak on the right. 
 
2.2.3. Surface staining protocol 
 
Mice  were  killed  with  isoflurane  inhalation.  The  two  groups  of  mice 
sacrificed  for  both  Carboxyfluorescein  diacetate  succinimidyl  ester  (CFSE) 
proliferation  assay  and  for  spleen  and  LN  cells  staining  were  transcardially 
perfused with Ringer’s solution for 15 minutes. The perfusion was performed in 
order to remove blood cells from the brain vasculature. Brains were frozen in 
isopentane chilled in liquid nitrogen and kept at -80°C. For further analysis, brains 
can be cut at the microtome and sections analyse by immunohistochemistry at the 
microscope. Bilateral inguinal lymph nodes and spleen were taken. Cells from 
spleen and LN were dissociated by forcing through 70 μm sterile cell strainer (BD 
Falcon)  using  HBSS  (Hanks  Balanced  Salt  Solution  1x)  containing  5%  of 
complement-inactivated  FCS  (Fetal  Calf  Serum,  Invitrogen).  They  were 
centrifuged at 1300 rpm for 5 minutes, the supernatant was discarded. Red blood 
cells in spleen were lysed with 3 ml ACK (lysing buffer), resuspended in 12 ml 
HBSS 10% FCS and centrifuged. LN and spleen cells were resuspended in 5 ml 
and  in  10  ml  HBSS  5%  FCS  respectively.  Live  cells  were  discriminated  by 
exclusion of Trypan Blue dye and they were counted with improved Neubauer 
counting  chamber.  Cells  were  used  for  this  protocol  and  also  for  the  CFSE 
proliferation assay (section 2.3.2.). They transferred to conical 3 ml tubes (106 
cells/ tube). They were washed with FACS® FWB (flow cytometer wash buffer), 
centrifuged and supernatant discarded. Cells were resuspended in 15 μl Fc-block 
(antibody which binds Fc-receptors, to prevent nonspecific bidings of monoclonal 
antibodies). Cell were then incubated at 4°C for 10 minutes. 15 μl of antibody mix 
was then added, cells were incubated 4°C for 20 minutes. Cells were washed with 
FWB, centrifuged and supernatant was discarded. 30 μl of secondary antibody 40 
 
mix  was  added  if  necessary,  cells  were  incubated  20  minutes  at  4°C.  Two 
repeated washes with FWB were finally performed. Cells were resuspended in 
300  μl  FWB  and  transferred  into  round-bottom  tubes,  read  on  a  Gallios  flow 
cytometer or kept at 4°C until their analysis. 
 
2.2.4. Intracellular staining protocol 
 
After  surface  staining,  an  intracellular  staining  to  analyse  the  INF-γ 
production was performed in the experiment discussed in section 2.4. The BD 
Cytofix/Cytoperm
TM Plus Fixation/Permeabilization kit was used. Supernatant was 
discarded and pellet was resuspended in 250 μl BD Fix/Perm solution. Cells were 
incubated 4°C for 20 minutes. Cells were then washed twice with 1 ml 1x BD 
Perm/Wash Buffer, centrifuged and supernatant was then discarded. Pellet was 
resuspended in 50 μl of intracellular antibody prepared in BD Perm/Wash Buffer, 
samples were incubated 30 minutes at 4°C. Cells were then washed twice with 1 
ml 1x BD Fix/Perm solution, centrifuged and supernatant was discarded. Cells 
were then resuspended in 200 μl FWB and transferred into round-bottom tubes, 
read on a Gallios flow cytometer or kept at 4°C until their analysis. 
 
2.2.5. Determination of cell numbers and viability by Trypan Blue exclusion 
 
Trypan blue is a vital stain used to discriminate live cells from dead ones. 
Live cells with intact cell membrane are not coloured and are bright, whereas the 
stain traverses the damaged membranes of dead cells and they appear blue at the 
microscope. Trypan Blue exclusion was adopted to identify live cells and cell 
counting was performed using improved NeuBauer counting chamber.  
 
2.3. CFSE PROLIFERATION ASSAY 
 
2.3.1. General principles of the technique 
 
CFSE has the ability to passively diffuse into cells, owing to the presence 
of two acetate groups that make the compound highly membrane permeable. Once 
inside  the  cell,  the  acetate  groups  are  removed  by  intracellular  esterases;  the 
compound become fluorescent and it is trapped inside the cell owing to reduced 
membrane permeability. CFSE is not transferred to adjacent cells. The staining 
persists  in  daughter  cells  and  the  fluorescence  is  diluted  at  each  division. 
Approximately 8 cell divisions can be identified before the CFSE fluorescence is 
too low for detection. In this experiment, proliferative ability of splenocytes from 41 
 
RasB8 transgenic and non-transgenic mice was tested. Cells were labeled with 
CFSE  and  then  were  cultured  with  Concanavalin  A  (ConA)  a  T  lymphocyte 
mitogen extracted from the jack-bean Canavalia ensiformis. ConA was used to 
non-specifically stimulate the proliferation of CFSE-labeled lymphocytes. 
 
 
 
 
 
Figure 9: CFSE fluorescence is diluted at each cell division. In this figure, the principles of 
CFSE proliferation assay are illustrated. At each cell division, CFSE fluorescence is diluted to 
daughter cells. In this case, four cell divisions are shown and labeled with numbers from 0 to 4. 
Cells which divided more are represented in yellow in the cartoon above; in the histogram, they 
are represented by the less fluorescent peak.  
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2.3.2. CFSE proliferation assay protocol 
 
As described in section 2.2.3, cells were counted for this experiment and 
for spleen and LN staining. 2x107 spleen cells were harvested in a 15 ml falcon 
tube  and  washed  twice  with  RPMI  1640  (Roswell  Park  Memorial  Institute 
medium 1640 1x) without FCS. Then they were resuspended in 1 ml RPMI 0% 
FCS containing CFSE (Molecular Probes) 5 μM. They were incubated 10 minutes 
at 37°C 8% CO2 and shaken once after 5 minutes. Then they were washed twice 
with  RPMI  10%  FCS  and  resuspended  in  5  ml  T  cell  medium.  Then  cell 
concentration was adjusted to 1.33x106 cell/ml. Then they were plated in a 96-
well plate (150 μl/ well). 50 μl of medium containing Concanavalin A (Sigma) 
was added to the wells to obtain two different final concentrations (2.5 μg/ml or 
0.5 μg/ml). The cells were incubated at 37°C 8% CO2 for 4 days. The cells were 
harvested  and  transferred  to  96-well  plates  with  conical  wells.  They  were 
centrifuged  at  1000  rpm  for  5  minutes  and  then  washed  with  FWB.  After 
discarding supernatant, cell were resuspended in 15 μl Fc-block and incubated for 
10 minutes at 4°C. Then 15 μl of antibody mix was added, cells were incubated 
4°C for 20 minutes. The cells were washed twice with FWB, lastly resuspended in 
200  μl  FWB  and  transferred  into  round-bottom  tubes.  They  were  read  on  a 
Gallios
TM  (Beckman  Coulter)  flow  cytometer.  Every  sample  was  analyzed  in 
quadruplicate. CD4-PE and CD8-APC antibodies were used. 
 
2.3.2. Data analysis 
 
Using Flowjo 7.2.5 software, the percentages of divided T cells after ConA 
stimulation were counted. Cells were gated on live lymphocytes according to size 
and granularity. In figure 10 are shown two different representative examples of 
graphs used to calculate the number of divided and not divided cells.  
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Figure 10: CFSE proliferation data analysis. Two pseudo colour graphs representative of CFSE 
proliferation assay data analysis. In FL1, CFSE fluorescence is displayed, whereas in FL6 and in 
FL2  fluorescence  of  CD8  and  CD4  antibodies  respectively  are  observed.  In  figure  A  and  B, 
proliferation of CD8 and CD4 T respectively is shown after 2.5 μg/ml ConA stimulation. Each cell 
population was gated according to the different level of CFSE fluorescence, from R0 to R4. 
 
 
On the X axis FL1 is displayed, which shows the read out of the CFSE 
fluorescence. FL6 and FL2, on the Y axis, correspond to CD8 and CD4 staining, 
respectively. Cells were gated in five different groups: R0 (not divided cells) and 
R1, R2, R3, R4 (divided cells). Only CD8 or CD4 positive cells were considered 
(upper region of the plot). The non divided cells (R0) are on the right side of 
graphs and have higher CFSE fluorescence. The cells which have proliferated 
more (R4), show decreased CFSE fluorescence (on the left side of the graphs). 
The percentage of divided cells was calculated as follow: 
 
 
 
 
 
Where: 
 
Total dividing cells = R1 + R2 + R3 + R4 
Total cells = total dividing cells + R0 
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2.4. DETECTION OF SPECIFIC ANTIGEN RESPONSE 
 
2.4.1. LacZ-recombinant vaccinia virus 
 
Vaccinia virus (VV) was commonly used to vaccinate against smallpox 
(caused by variola virus) and it is a useful expression vector. In this experiment, 
LacZ-recombinant  VV  virus  (VV-LacZ)  (kindly  provided  by  D.  Pinschewer, 
University of Geneva, Switzerland) was used. LacZ is the gene which encodes for 
β-galactosidase  (βgal),  an  enzyme  which  catalyses  the  hydrolysis  of  β-
galactosides into monosaccharides. As previously explained, in the RasB8 mouse 
model, transformed astrocytes express this protein under GFAP promoter control 
(see figure 5). Thus βgal is considered an antigen specifically expressed on glial 
cells and potentially presented on MHC class I. In this experimental work, two 
βgal  peptides  (Biomatik,  USA)  were  used:  DAPIYTNV  (βgal96-103)  and 
ICPMYARV  (βgal497-504),  corresponding  to  two  proposed  immunodominant 
epitopes able to bind to the MHC class I allele H-2K
b. 
 
 
2.4.2. Resume of the experiment  
 
In this experiment, RasB8-129 mice were used. The aim of the experiment 
was  to  determine  if  a  tumour  Ag-specific  T  cell  response  can  be  detected 
peripherally after VV-LacZ vaccination and subsequent in vitro cell stimulation. 
The following figure clarifies the experimental procedure: 
 
 
 
 
 
Mice were sacrificed one week after VV-LacZ vaccination, the expected 
peak  of  immunological  response.  Ex-vivo  staining  was  performed  in  order  to 
verify  T  cell  activation;  mice  were  selected  according  to  the  proportion  of 
activated  cells  and  cell  growth  observation  performed  at  the  microscope. 45 
 
Stimulation of cells was performed with DAPIYTNV and ICPMYARV peptides. 
In order to confirm an immunological response against the virus, vaccinia virus 
peptide  (VV  peptide,  TSYKFESV,  B8R20–27)  stimulation  was  performed.  Cells 
grown without antigen were used as negative control. Cells were also cultured 
with  ConA  to  assess  their  capacity  to  proliferate  under  mitogen  non-specific 
stimulus. For cell re-stimulation, peptides and irradiated C57BL/6 mice spleen 
cells  were  used.  Irradiation  was  performed  to  prevent  cell  proliferation.  As 
control, irradiated cells were plated and no proliferation was observed. For the 
final 6 hour of incubation, before INF-γ staining, ionomycin (iono) (Sigma) and 
phorbol  12-myristate  13-acetate  (PMA)  (Sigma)  incubation  was  performed. 
Iono/PMA  incubation  activates  lymphocytes.  In  particular,  ionomycin  is  an 
ionophore  produced  by  the  bacterium  Streptomyces  conglobatus;  it  raises  the 
intracellular levels of calcium (Ca2+). PMA is diester of phorbol and activates 
protein kinase C (PKC).  
 
2.4.3. Mice vaccination, sacrifice and cell culture 
 
Mice were vaccinated intraperitoneally with 2x106 plaque-forming units 
(PFu) of VV-LacZ. After one week, they were sacrificed by isoflurane inhalation. 
Spleens were taken and cells were dissociated by forcing through a 70 μm sterile 
cell strainer using HBSS containing 5% of complement-inactivated FCS. Cells 
were centrifuged at 1300 rpm for 5 minutes, the supernatant was discarded. Red 
blood cells were lysed for one minute with 2 ml ACK, then resuspended in 10 ml 
HBBS 5% FCS. Cells were then counted. 106 cells were harvested in one conical 
tube  and  used  for  ex-vivo  staining  (section  2.4.4.).  For  each  spleen,  5x106 
cells/well and 2.5x106 cells/well were plated in 24-well plates at five different 
conditions: T cell medium only  (final volume of 1 ml), ConA (1 μg/ml), VV 
peptide (10 μg/ml),  ICPMYARV peptide (10 μg/ml), DAPIYTNV peptide (10 
μg/ml). To each well, 30 U/ml of IL-2 were added, in order to stimulate T cells 
expansion. Cells were kept on culture at 37°C, 5% CO2 for one week. At day 4, 
500 μl of medium were removed and 500 μl of fresh T cell medium supplied with 
30 U/ml IL-2 were added. 
 
2.4.4. Ex-vivo staining 
 
Ex-vivo  splenocyte  staining  was  performed  on  day  of  sacrifice  to 
determine the activation of CD8
+ and CD4
+ T cells one week  after  VV-LacZ 
vaccination,  using  surface  staining.  All  procedures  were  performed  in  a  P2 
laboratory  and  cells  were  fixed  after  antibody  staining  using  FWB  fix  buffer 46 
 
(Flow cytometer Wash Buffer with Fixative) for the last two washes. Antibodies 
used were: CD4 APC/Cy7, CD8 APC, CD44 FITC and CD62L PE. 
 
2.4.5. Cell re-stimulation 
 
Splenocytes were re-stimulated with the three different peptides previously 
mentioned after one week-culture. Re-stimulation was performed using C57BL/6 
spleen cells. C57BL/6 mice were sacrificed; spleen cells were taken and counted 
as previously described. The cell number required in each well for re-stimulation 
was 5x106 cells. Cells were centrifuged and divided in three 15 ml falcon tubes 
according to the cell number required. Then they were resuspended in 10 ml T 
cell medium. VV, ICPMYARV, DAPIYTNV peptides were added to the tubes at 
a final concentration of 10 μg/ml. Cells were then incubated for 90 minutes at 
37°C 5% CO2 and then irradiated at 100 Gy. Cells were then washed twice with 
HBSS medium 5% FCS. They were finally re-suspended at the required volume 
in 90 U/ml IL-2 CTL medium. 500 μl of medium was removed from each culture 
well and 500 μl of prepared cell suspension for re-stimulation was then added to 
each well. Fresh 90 U/ml IL-2 CTL medium was added to wells not stimulated 
with peptides. 
 
2.4.6. INF-γ staining 
 
Seven  days  after  re-stimulation,  cells  underwent  5-hour  peptide  or 
iono/PMA stimulation before intracellular INF-γ staining. Wells were carefully 
washed twice and cells were collected and re-suspended in T cell medium. Cells 
which  were  stimulated  with  peptides  were  split  in  two  different  tubes  to 
performed peptide or iono/PMA stimulation. Cells stimulated with ConA were not 
analysed, but their growth was observed at the microscope as a positive control. 
Cells were centrifuged at 1500 rpm for 6 minutes and supernatant was discarded. 
1  ml  of  T  cell  medium  containing  different  peptides  at  the  established 
concentrations was then added; in iono/PMA stimulation tubes ionomycin was 
added at 1 μg/ml and PMA at 100 ng/ml. Cells were incubated for 1 hour at 37°C 
5% CO2. BD Golgi Stop™ was then added to each sample (1:1000 diluition) and 
then  4  hour  incubation  was  performed. After  incubation,  surface  staining  was 
performed using the following antibodies: CD8 APC, CD4 PE and CD44 FITC. 
Then INF-γ intracellular staining (INF-γ PE/ Cy7) and isotype (IgG1 PE /Cy7) 
control staining were performed.  
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2.5. STATISTICAL ANALYSIS 
 
Statistical  analyses  were  performed  using  Sigma  STAT®  software.  P-
values were considered statistically significant if < 0.05.  
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3. RESULTS 
 
In this experimental work, we investigated the peripheral immune status of 
RasB8 astrocytoma mouse model, functionally and phenotypically. We analysed 
in vitro responsiveness of T cells to mitogen and we performed surface staining of 
splenocytes and LN cells. Furthermore, we analysed peripheral responsiveness to 
a tumour-associated antigen. This chapter is divided according to the two different 
experimental approaches. 
 
3.1. SPLENOCYTES AND LN ANALYSIS 
 
In this experiment, we used RasB8-CD1 mice. We tested two different 
groups  of  mice  with  their  corresponding  control  groups.  The  first  group  was 
constituted by six 4-6 week-old (wo), asymptomatic transgenic mice whereas six 
non-transgenic, littermate mice composed the control group. The second group 
was formed of six ill, older mice (> 12 weeks old) and its control group by six 
non-transgenic, age-matched mice. We performed surface staining of splenocytes 
and LN cells and CFSE proliferation assay. 
 
3.1.1. Surface staining of splenocytes and LN cells 
 
We sacrificed mice and we took spleen and inguinal lymph nodes. We 
isolated  cells  and  then  we  lysed  red  blood  cells  from  spleen.  After  that,  we 
performed  surface  staining  to  analyse  leucocyte  subpopulations,  using  the 
following markers: Gr-1, CD4, Ly-6C, CD11b, B220 and CD8.  
 
3.1.2. Quantitative analysis of T and B cells in spleen and LN 
 
We calculated percentages of B cells (B220
+), CD4 T cells and CD8 T 
cells related to the total live leucocytes in spleen and in lymph nodes. We also 
calculated the ratio of CD4/CD8 T cells. With respect to B cells (figure 11A), 
there were always higher cell percentages in spleen than in LN (in spleen the 
mean of all groups is 42.4 ± 5, in LN 12 ± 2). No significant differences were 
observed between groups. CD4 T cells (figure 11C) are more represent in LN than 
in spleen. A significant difference was observed only in LN, between ill RasB8 
mice and littermate group. As for CD4 T cells, CD8 T cells (figure 11B) are 
presented at higher percentages in LN. No significant differences were observed 
between groups for both organs. The ratio CD4/CD8 (figure 12) is significantly 49 
 
different  between  ill  RasB8  mice  and  littermates  in  LN.  In  spleen,  the 
corresponding percentages follow the same trend.  
 
 
 
Figure 11: CD4 T cells are significantly diminished in ill RasB8 mice LN. Spleens and LNs 
were taken from the indicated groups. Cells were prepared from individual mice; they were surface 
stained with antibody to B220 (A), antibody to CD8 (B) and antibody to CD4 (C) and analysed by 
flow  cytometry.  Cell  percentages  in  the  leucocyte  gate  are  shown.  Group  means  ±  standard 
deviation (SD) are displayed. P-value was calculated with unpaired Student t-test. 
 
    
 
Figure 12: LN cells of ill RasB8 mice have a decreased CD4/CD8 ratio. Proportions of CD4 
and CD8 cells in lymphoid tissues and spleens of the indicate groups of mice were obtained from 
flow cytometry analysis and ratios were calculated. Bars indicate means ± SD of mouse groups. P-
value was calculated using an unpaired Student t-test. 
 
 50 
 
3.1.3. Memory CD4 and CD8 T cells: Ly-6C marker 
 
We  analysed  the  expression  of  the  Ly-6C  marker,  proposed  to  be 
associated  with  memory  function,  in  CD4  and  CD8  T  cells.  We  gated  cells 
according  to  their  positive  expression  of  CD4  or  CD8,  then  we  detected 
subpopulations expressing high level of the memory marker using histograms. We 
analysed cells from both LN and spleen. With respect to CD4
+ cells in the LN, 
two  distinctive  cell  subpopulations  which  differently  express  Ly-6C  were  not 
observed in the majority of samples (data not shown). For this reason, no graph 
showing  LN CD4
+  Ly-6C
high cells  are displayed in  this  section. In all graphs, 
100% is equal to the total number of cells in CD4
+ or CD8
+ population.  
There were no significant differences between groups for CD4
+ Ly-6C
high 
cells (figure 13). Concerning CD8
+ cells, there was a trend towards higher Ly-6C 
expression on CD8
+ cells in older mice, but this was not statistically significant 
(figure 14). 
 
 
 
 
Figure  13:  No  differences  in  CD4
+  Ly-6C
high  splenocyte  percentages  between  RasB8  and 
control groups. Cell percentages were obtained from flow cytometry analysis; lymphocytes were 
gated according to positive expression of CD4. CD4 T cells from LN are not displayed because a 
CD4  positive  subpopulation  expressing  high  level  of  Ly-6C  was  not  detected  in  all  samples. 
Means of different groups ± SD are displayed. 
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Figure 14: A trend towards higher percentages of CD8
+ Ly-6C
high cells is observed in older 
rather  than  in  younger  mice.  Means  ±  SD  of  mouse  groups  are  shown.  A  flow  cytometry 
analysis was performed; splenocytes and LN cells were gated according to their CD8 positive 
expression. 
 
 
3.1.4. Myeloid-derived suppressor cells 
 
The  MDSCs  are  a  group  of  myeloid  cells  including  precursors  of 
macrophages, granulocytes, dendritic cells and myeloid cells at earlier stages of 
differentiation (Youn et al., 2008).  
 
 
 
Figure  15:  Myeloid-derived  suppressor  cells  are  detected  in  all  mice.  Gr-1
+  CD11b
+  cells 
(MDSCs)  were identified by flow  cytometry of surface stained  splenocytes. Percentages  were 
calculated in the total large  granular cell (FCS
high SSC
high) gate. Means of defined groups are 
displayed; error bars represent SD. 
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MDSCs are able to suppress T cell responses and circulating MDSCs are 
found to be increased in cancer patients. In mice, they are generally defined as Gr-
1
+  CD11b
+  cells  (Youn  et  al.,  2008).  We  detected  Gr-1
+  CD11b
+  splenocytes 
(figure 15) but there were no significant differences between tumour-bearing, ill 
and control mice. 
 
3.1.5. CFSE dilution assay for in vitro T cells proliferative response  
 
To determine the proliferative capability of peripheral T cells, we used a 
CFSE proliferation assay. Lymphocytes that were employed for spleen and LN 
staining  were  also  utilised  in  this  test.  We  labelled  the  cells  with  CFSE,  a 
fluorescent compound which is incorporated in cells and is diluted in daughter 
cells  at  each  cell  division  (see  section  2.3.1.),  and  we  stimulated  the  CFSE-
labelled cells in vitro for 4 days with the polyclonal mitogen ConA. We tested two 
different  concentrations  of  the  mitogen.  At  day  5,  we  harvested  the  cells  and 
stained them for CD4 and CD8. Percentages of dividing cells were calculated as 
explained in section 2.3.3.  
 
3.1.6. Results of proliferation assay 
 
We analysed both CD4 and CD8 T cell response to ConA at low (0.5 
µg/ml) and high (2.5 µg/ml) concentration.  
 
Figure 16: ConA dose-dependent proliferation of CD4 and CD8 T cells. Spleen cells from 
indicated mouse groups were CFSE labelled and stimulated  in vitro for 4 days with low (0.5 
µg/ml) and high (2.5 µg/ml) concentration of the mitogen ConA. Dividing cell percentages were 
calculated as explained in section 2.3.3. Means   SD are shown. 
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We measured the responsiveness of splenocytes as percentage of dividing 
cells of either the CD4 or CD8 gated populations (figure 16). We observed that 
between 60% and 91% of cells from individual mice proliferated with low dose 
ConA, and more than 95% of cells proliferated with high dose ConA. We did not 
found significant differences between mouse groups. 
 
3.2. IN VIVO PRIMED T CELL IMMUNE RESPONSE 
 
In  this  experiment,  we  used  RasB8-129  mice  to  asses  in  vivo  T  cell 
function. The specific immune response was analysed at the peripheral level, in 
particular after in vitro re-stimulation of mouse splenocytes. We infected mice 
with  live  recombinant  VV-LacZ.  This  procedure  can  vaccinate  mice  against 
antigens encoded in the viral sequence (VV, Lac-Z).  
 
Mice  were  divided  into  three  different  groups:  transgenic  (TG),  non 
transgenic (NTG) and control. The latter was formed by two non transgenic non-
vaccinated mice. Both transgenic and non transgenic mice groups were composed 
of six  mice;  four of them  were selected for the last  analysis according to  the 
immune cell activation status and according to the cell growth observed in vitro. 
 
3.2.1. LacZ Vaccinia Virus vaccination and mouse sacrifice 
 
We vaccinated transgenic and non transgenic mice with VV-LacZ virus by 
intraperitoneal injection. Mice were sacrificed seven days after vaccination. We 
utilised non vaccinated mice as control. 
 
3.2.2. Ex-vivo phenotype 
 
T  cell  activation  status  was  investigated  to  assess  whether  there  was 
significant T cell stimulation by the vaccination. Splenocytes were stained ex-vivo 
7 days after vaccination, the predicted peak of the antiviral immune response. We 
assessed activation by high expression of CD44 and low expression of CD62L. In 
fact,  in  activated  cells  CD44  is  highly  expressed  whereas  the  expression  of 
CD62L is low. We observed differently activated cell populations (figure 17). In 
vaccinated mice, the percentage of activated cells is higher (CD62L
low CD8
+ and 
CD44
high  CD8
+  in  NTG  mouse,  CD44
high  CD8
+  in  TG  mouse)  or  comparable 
(CD62L
low  CD8
+  in  TG  mouse)  to  the  percentage  of  non-activated  cells. 
Conversely, in non vaccinated mice, we observe that non-activated cell percentage 
is  greater  than  activated  cell  percentage.  Although  we  cannot  measure  the 54 
 
activation  status  of  splenocytes  of  the  same  mice  before  vaccination,  all 
vaccinated mice had higher proportions of activated CD8 T cells than the non-
vaccinated controls. 
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Figure 17: Differently activated CD8 T cell subpopulations after VV vaccination. Activation 
status of CD8 T cells was tested 7 days after recombinant VV vaccination in transgenic and non 
transgenic RasB8 mice. Different dot plots show representative examples of ex-vivo splenocyte 
staining. Cell activation was determined using CD44 and CD62L markers. Activated CD8 T cell 
subpopulations are highlighted with red rectangle. Non vaccinated mice were used as negative 
control. 
 
 
Furthermore, we used the absolute number of cells to compare activated 
cells from different mouse groups. The absolute number was calculated referring 
to the amount of cells counted before the surface staining. We gated the cells 
according to the positive expression of CD4 or CD8; then we obtained proportions 
of these cells which were CD62L
low and CD44
high. In figure 18, the number of 
activated CD8 T cells is shown. There was a high standard deviation above all for 
NTG  mouse  group.  We  observed  a  statistically  significant  difference  only 
between the TG and the control group; the high SD in the NTG mouse group may 
influence the lack of statistical power for CD8 activated cells. We focused our 
attention on CD8
+ cells rather than CD4
+ cells because the former is the principle 
cellular type involved in the specific response we investigated. Moreover, we did 
not obtain statistically significant differences in the percentages of activated CD4 
cells between groups (data not shown).  
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Figure 18: Significant augmentation of activated CD8 T cell in vaccinated mice. Transgenic 
and  non  transgenic  RasB8  mice  were  vaccinated  with  recombinant  VV  virus;  CD8  T  cell 
activation status was tested 7 days after vaccination (immune response peak). Activated CD8 T 
cell number was determined by flow cytometry analysis. P-value was calculated with an unpaired 
Student t-test. Group means ± SD are shown.  
 
 
3.2.3. In vitro re-stimulation  
 
We cultured mouse splenocytes and re-stimulated them in vitro. For re-
stimulation, diverse peptides were tested: a viral peptide sequence (VV peptide) 
and two different βgal peptides (ICPMYARV and DAPIYTNV), from the protein 
encoded by the LacZ gene. To define cell growth, we used cell culture medium in 
negative control wells and ConA in positive control wells. To facilitate T cell 
growth, IL-2 was added in each well. After 7 days culture, re-stimulation was 
performed  using  irradiated  C57BL/6  splenocytes  previously  incubated  with 
different peptides. Cells cultured with ConA did not undergo re-stimulation with 
irradiated  splenocytes.  In  negative  control  cell  wells,  we  utilised  irradiated 
splenocytes (without specific peptide) for cell re-stimulation. 
 
3.2.4. Selection of spleens for INF-γ production analysis 
 
In this experiment, six transgenic and six non transgenic RasB8-129 mice 
were sacrificed. Four mice per group were selected for INF-γ staining, according 
to the percentages of ex-vivo stained activated CD8 T cells and according to the 
capacity of splenocytes to grow in vitro after stimulation and re-stimulation (table 
4).  
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Mice 
 
Number of 
cells / spleen  
( x 106 ) 
 
 
% 
CD62low 
cells in 
CD8+  
 
% 
CD44high 
cells in 
CD8+  
 
 
In vitro 
growth  
(day 6) 
 
In vitro 
growth 
(day 11) 
1  TG  59  28  65  ++  + 
2  TG  72  31  51  ++  + 
3  TG  92  26  36  +  - 
4  TG  70  42  65  +  +/- 
5  TG  62  46  70  +/-  +/- 
6  TG  81  49  72  +/-  +/- 
7  NTG  93  34  77  +/-  + 
8  NTG  114  54  85  +  +/- 
9  NTG  75  33  54  +/-  +/- 
10  NTG  90  33  68  +/-  +/- 
11  NTG  54  41  67  +  - 
12  NTG  70  44  72  +/-  +/- 
13  control  92  12  41  +/-  +/- 
14  control  49  11  29  +/-  +/- 
 
Table 4: Selection of activated splenocytes for INF-γ production analysis. Transgenic and non 
transgenic RasB8 mice were vaccinated with Lac-VV and sacrificed after 7 days. Spleen cells 
were isolated and stimulated in vitro. Splenocytes were selected for INF-γ production analysis 
according to CD8 T cell activation status and to growth in vitro of VV peptide-stimulated cells. 
Cell  growth  was  evaluated  as  follows:  (++)  number  of  lymphocytes  higher  than  in  negative 
control, activated lymphocytes; (+) number of lymphocytes comparable to the control, only few 
cells  activated;  (+/-)  number  of  cells  comparable  to  cells  in  control  wells,  no  activated 
lymphocytes; (-) lower amount of cells than in control wells. Selected mice are displayed in red; 
the cell absolute number is based on the cell count performed before the ex-vivo surface staining. 
 
 
A  vigorous  anti-viral  immune  response  may  result  in  major  clonal 
expansion  of  lymphocytes  in  the  spleen.  We  therefore  preferentially  selected 
spleens with high cell yield for further analysis. Both CD44 and CD62L markers 
were considered in the selection. With respect to cell growth in vitro, there was no 
clear correlation of cell number or activation status (scored as in vitro growth in 
table 4) with the different peptide stimulations. The transgenic and non transgenic 
selected mice are visible in red in table 4. 
 
3.2.5. INF-γ production 
 
After in vitro βgal peptides stimulation, we re-stimulated splenocytes with 
the  two  respective  βgal  peptides;  then  we  performed  the  intracellular  INF-γ 
staining.  Cells  from  non  vaccinated  mice  were  used  as  negative  control.  Re-
stimulation with ionomycin and PMA was also performed in order to prove the 
lymphocyte ability to become activated and to secret INF-γ.  58 
 
In  figure  19,  different  representative  histograms  of  INF-γ  staining  are 
shown. Only DAPIYTNV stimulated cells are illustrated as example. Increased 
INF-γ production is noticed in the transgenic mouse, although also in NTG mouse 
a percentage of INF-γ positive cells is observed. In non vaccinated mice, we do 
not  notice  INF-γ  production  after  DAPIYTNV  stimulation.  We  observe  that 
iono/PMA stimulation induced more response in non vaccinated mouse than in 
vaccinated ones. 
 
                 DAPIYTNV stimulation                Iono/PMA stimulation 
 
 
 
 
                DAPIYTNV stimulation                  Iono/PMA stimulation 
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               DAPIYTNV stimulation                Iono/PMA stimulation 
 
 
 
Figure 19: INF-γ production after peptide stimulation is observed only in vaccinated mice. 
RasB8 mice were vaccinated with VV-LacZ and isolated splenocytes were stimulated in vitro. 
Selected CD8
+ CD44
high splenocytes from transgenic, non transgenic and control (non vaccinated) 
mice  were  analysed  after  DAPIYTNV  and  iono/PMA  re-stimulation  for  INF-γ  production. 
Illustrative  histograms  obtained  with  flow  cytometry  analysis  are  shown.  Only  the  antibody 
staining is illustrated. INF-γ positive cells (red line) are displayed.  
 
 
 
 
Figure 20: Trend towards higher INF-γ production in transgenic rather than non transgenic 
mice after peptide stimulation. INF-γ production was measured in stimulated splenocytes from 
both RasB8 transgenic and non transgenic mice. Lymphocytes were gated and CD8
+ CD44
high 
stained cells were analysed with flow cytometer. Percentages were calculated subtracting INF-γ 
isotype staining values. Means of different groups (n=4) ± SD are shown. 
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The two different βgal peptides we used for splenocyte stimulation to INF-
γ production are DAPIYTNV and ICPMYARV. INF-γ production was measured 
in CD8
+ CD44
high cells from both transgenic and non transgenic mice (figure 20). 
A modest trend to have more production of INF-γ in transgenic mice is noticed, 
although no significant differences were calculated between groups. Overall, the 
percentages of positive cells that we obtained are at the limit of detection for both 
transgenic and non transgenic mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 61 
 
4. DISCUSSION 
 
 
4.1. PERIPHERAL IMMUNE BALANCE IN GLIOMA 
 
Defects  in  immune  cellular  function  of  glioma  patients  have  been 
documented, demonstrating that a solid tumour arising in brain is able to influence 
peripheral immune functions through soluble factors (Fecci et al., 2006; Dix et al., 
1999).  In  glioma  patients  there  is  evidence  of  cutaneous  anergy  to  common 
bacterial antigens, T cell hyporesponsiveness and lymphopenia (Morford et al., 
1997). With respect to a quantitative analysis of different types of cells, it has 
been demonstrated that relative number of peripheral blood CD4 and CD8 T cells 
in patients is shifted from normal: CD4 T cells are greatly diminished in glioma-
bearing individuals (Waziri, 2010).  
The RasB8 astrocytoma model was used in this study, to investigate the 
balance of different types of leucocytes at the peripheral level, in particular in 
spleen and in inguinal lymph nodes. 
 
4.1.1. Glioma does not have a major impact on B cell proportions 
 
A study on the percentage and on the absolute number of B cells in blood, 
showed  similarities  between  glioma  patients  and  healthy  donors.  Furthermore, 
immune defects in glioma patients were demonstrated to involved T cell subsets 
rather than B cells (reviewed by Dix et al., 1999).  
Our data showed no significant differences in B cell proportions between 
RasB8 and control mouse groups, in both spleen and LN (figure 11 A). B cell 
proportions  in  transgenic  ill  mice  are  characterised  by  the  highest  standard 
deviation; this may be due to the different disease status of the mice that are only 
crudely graded as “ill”.  
Overall, from the literature and our study, B cells do not appear to be a 
major target of glioma-mediated immunosuppression. However, to fully exclude 
this, we could also need to examine the bone marrow as another major site for B 
cells, and antibody titres as indicator of B cell function.  
 
4.1.2. The proportion of CD4 T cells can be reduced in RasB8 glioma 
 
As previously discussed, it is demonstrated that peripheral blood CD4 T 
cells  in  glioma  patients  are  diminished  in  comparison  to  healthy  donors  and, 
consequently, the ratio CD4/CD8 T cell is altered (Waziri, 2010).  62 
 
Indeed, with respect to CD4 T cell proportion, we observed a significant 
difference in LN T cells of ill RasB8 mice in comparison to control group (P= 
0.003), demonstrating the fact that CD4 T cells proportion is diminished in old, 
symptomatic  mice.  However,  in  younger,  asymptomatic  mice,  no  significant 
differences were found. Differently to LN, in spleen CD4 T cell proportion is not 
significantly altered between groups.  
Concerning CD4/CD8 T cell ratio, we observed a significant difference 
(P= 0.02) between ill RasB8 mice and littermate group in LN; in spleen, the same 
trend  is  observed  (P=  0.06),  although  this  is  not  statistically  significant.  To 
explain  the  differences  observed  between  lymph  nodes  and  spleen  cell 
proportions, it can be hypothesized that in ill mice the lymphocyte recirculation 
can  be  perturbed  due  to  the  impaired  muscle  tone,  essential  for  efficient 
lymphocyte recirculation through lymphatics. Ill mice are in fact visibly weak and 
their capacity of movement is limited. Indeed, lymphocyte trafficking from lymph 
nodes  depends  up  on  the  lymphatics  and  requires  muscular  movement  and 
tonicity.  In  contrast,  lymphocytes  enter  and  exit  spleen  by  means  of  venous 
circulation, which may be preserved even in ill mice.  
Overall, significant differences between CD4 T cell proportions are shown 
only if mice exhibit symptoms and are at the latest stages of the disease. We did 
not  observe  alterations  in  younger  mice.  In  conclusion,  RasB8  mice  immune 
balance is unpaired only at later stages of the disease, differently to local immune 
balance, altered from early stages (Tran Thang et al., 2010). Moreover, alteration 
in T cell proportion is manifested within the CD4 T cell compartment rather than 
CD8, comparable to what is described in human glioma (reviewed in Fecci et al., 
2006).  
 
4.1.3. Memory phenotype T cells remain intact in RasB8 glioma 
 
One  of  the  most  relevant  characteristics  of  adaptive  immunity  is  the 
capacity  to  provide  long-term  immunological  memory  (Parham,  The  immune 
system, 2009). Memory cells play an important role in immune responses; they 
rapidly respond to antigen and have an extended lifespan (Tokoyoda et al., 2009).  
To investigate if glioma influences memory T cell proportion, we analysed 
Ly-6C  expression  in  RasB8  CD4
+  and  CD8
+  spleen  and  LN  T  cells.  Ly-6C 
belongs  to  the  Ly-6C  family  of  surface  glycoproteins  and  it  is  a 
glycosylphosphatidylinositol-anchored  molecule.  Ly-6C  is  expressed  on 
peripheral T cells in mice bone marrow and spleen after immunization (Tokoyoda 
et al., 2009), suggesting that Ly-6C might be associated with differentiation and 
activation of T cells. Indeed, Ly-6C is considered a memory marker of CD8 T 63 
 
cells (Walunas et al., 1995) and of CD4 T cells (Tokoyoda et al., 2009); in both 
cases it is expressed at high level. 
With respect to CD4 T cells, there were no significant differences between 
groups. Furthermore, in lymph nodes the CD4
+ Ly-6C
high T cell subpopulation was 
not detected (data not shown). Our data are in line with previous studies, in which 
memory CD4 T lymphocytes were demonstrated to be represented by a higher 
number in spleen than in lymph nodes (Tokoyoda et al., 2009). 
Additionally, we observed that memory phenotype CD8 T cells are not 
statistically  altered  in  transgenic  mice,  both  in  spleen  and  LN.  However,  to 
completely  investigate  proportions  of  this  cell  subset,  we  would  also  need  to 
utilise the activation marker CD44. In fact, it was demonstrated that  Ly-6C is 
expressed on previously activated cells and its expression is acquired only after 
CD44 expression (Walunas et al., 2005).  
In conclusion, we demonstrated that glioma does not impact memory T 
cell proportions. However, to perform a complete study on memory cells it would 
be also interesting to analyse bone marrow cells, since it is well-established that 
many memory T cells reside in that tissue. 
 
4.1.4. Myeloid-derived suppressor cell proportion is not increased in RasB8 
glioma 
 
Diverse  mechanisms  are  implicated  in  glioma  immune  suppression;  an 
important role is played by immunosuppressive cells: myeloid-derived suppressor 
cells (MDSCs), regulatory T cells and mesenchymal stem cells  (Walker et al., 
2009). Circulating MDSCs were found to be significantly increased in patients 
bearing different cancers of all stages, relative to healthy volunteers (reviewed by 
Youn et al., 2008). MDSCs suppress T cell responses in a specific or non-specific 
manner (reviewed by Youn et al., 2008).  
We investigated if tumour induces a peripheral increase in RasB8 spleen 
MDSCs: we did not observe statistically significant differences between glioma-
bearing mice and control group. Our results are discordant with another study in 
which increased MDSC proportions in spleen were observed in ten different mice 
tumour models (Youn et al., 2008), however in this study brain tumours were not 
examined. 
In conclusion, it cannot be state that MDSCs play an important role in 
glioma  peripheral  immunosuprression.  Moreover,  at  the  local  level  the 
contribution of MDSCs to the brain tumour infiltrate was not significant in most 
mice (Tran Thang et al., 2010).  
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4.2.  T  CELLS  DO  NOT  EXHIBIT  IMPAIRED  IN  VITRO 
FUNCTIONALITY IN RASB GLIOMA 
 
It  is  well-established  that  patients  with  glioma  exhibit  T  cell 
hyporesponsiveness (reviewed in Morford et al., 1997). Indeed, in vitro studies 
showed  that  peripheral  blood  lymphocytes  obtained  from  glioma  patients 
proliferated poorly in response to mitogen or antigen stimulation (reviewed by 
Dix et al., 1999). Defects of T cell responsiveness may depend on defects in early 
transmembrane signalling (Morford et al., 1997) and on Treg activity (Fecci et al., 
2006). 
We  performed  splenocyte  Concanavalin  A  in  vitro  stimulation  to 
determine if T cells in RasB8 mice are hyporesponsive in vitro, as in patients. We 
observed  that  the  T  cell  response  is  mitogen  dose-dependent.  There  were  no 
significant  differences  between  dividing  T  cell  proportions  in  different  mouse 
groups, even in the CD4 subset in which T cell hyporesponsiveness was observed 
in patients (reviewed in Fecci et al., 2006). 
It is noteworthy that we performed an in vitro test: we indeed measured T 
cell responsiveness once cells were removed from the in vivo environment. This 
study did not reproduce immunosuppressive molecules and soluble factors which 
in  vivo  may  influence  cell  proliferative  capacity.  Importantly,  a  correlation 
between the presence of the tumour and T-cell abnormalities has been discussed 
(reviewed by Waziri, 2010).  
Overall, these data suggest that glioma peripheral T lymphocytes do not 
show defective proliferation capability in vitro. However, the lack of influence by 
the immunosuppressive environment has to be considered. 
 
4.3. ACTIVATED T CELLS DO NOT RESPOND TO GLIOMA ANTIGEN  
 
It  is  demonstrated  that  glioma  patient  T  cells  exhibit  anergy  in  vitro 
(Morford et al., 1997). Furthermore, diverse peripheral immune defects suggest 
that immune responses at the peripheral level are impaired rather than functional 
(reviewed in Dix et al., 1999).  
We  investigated  T  cell  capacity  of  activation  and  peripheral  tumour-
antigen specific immune response in RasB8 mice. In order to enhance or elicit a 
peripheral  immune  response,  we  performed  a  recombinant  virus-mediated 
vaccination, using VV-LacZ. It encoded the β-galactosidase gene, which is also 
present  in  the  mouse  transgenic  construct.  Effects  of  this  immonuotherapeutic 
approach  were  previously  tested  at  the  local  level  in  RasB8  mice:  after 65 
 
vaccination,  T  cells  infiltrated  more  the  brains  of  transgenic  mice  and  had 
enhanced capacity to express INF-γ (Tran Thang et al., 2010). 
We observed that T cell in vivo capacity of activation is not affected in 
transgenic mice. To determine the efficacy of the VV vaccination, we investigated 
the activation status of CD8 T cells. There were significant differences between 
transgenic vaccinated and non transgenic non vaccinated mice. Non transgenic 
mice  also  show  an  activated  T  cell  phenotype,  but  there  was  no  statistically 
difference with transgenic mice. However, we did not use aged-matched mice and 
high variability (due to diverse immune conditions of individual mice) may have 
limited the sensitivity of our test to detect minor defects..  
With  respect  to  antigen  specific  immune  response,  we  measured  the 
expression  of  INF-γ  in  β-galactosidase  peptide  stimulated  transgenic  and  non 
transgenic RasB8 splenocytes. We tested CD8
+ CD44
+ T cells only, in order to 
accurately identify the cell population completely activated and specific for the 
peptide of interest. We obtained positive stained cells, but this was at the limit of 
detection, in both transgenic and non transgenic mice. There were no significant 
differences between groups, although a trend to have more INF-γ production was 
observed in transgenic mice. 
Overall, a specific immune response was not observed in RasB8 transgenic 
mice,  although  the  capacity  of  T  cells  to  become  activated  is  comparable  to 
control mice. Two different aspects have to be taken in consideration to consider 
these results. i) The specific immune response elicited by the recombinant VV 
backbone compared to that directed against the inserted gene was demonstrated to 
be 20-fold greater (Harrington et al., 2002). However, the response to the foreign 
gene is coordinately regulated with response to the vector. It can be hypothesised 
that  the  greater  immune  response  elicited  specifically  against  virus  backbone 
epitopes  might  have  prevented  the  boosting  of  the  specific  response  for  the 
inserted  gene.  Indeed,  although  we  did  not  measure  INF-γ  stimulated  by  VV 
peptides in these experiments, a parallel study of brain infiltrating T cells did 
detect VV-specific T cells that had infiltrated the brain of transgenic mice (Tran 
Thang et al., 2010). It could be interesting to adopt another approach for mouse 
vaccination in order to determine if VV vaccination is appropriate to elicit both a 
VV  and  a  βgal  specific  response,  or  if  peripheral  tolerance  to  the  tumour 
associated  antigens  is  present  in  RasB8  mice.  ii)  We  used  two  different  βgal 
peptides; both of them can be hypothesised to be insufficiently immunogenic to 
elicit  a  strong  specific  response.  To  verify  their  immunogenicity,  it  would  be 
interesting to analyse specific immune response to other different βgal epitopes. 66 
 
In conclusion, although RasB8 T cells are not able to exhibit functional 
βgal  specific  immune  response  after  recombinant  virus  vaccination,  this  may 
reflect an inefficient vaccine, as their capacity to become activated was unaltered.  
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5. CONCLUSIONS 
 
The  aim  of  this  thesis  was  to  analyse  the  peripheral  immune  status  in 
transgenic  RasB8  mouse  astrocytoma  model.  We  did  not  found  a  significant 
imbalance in spleen and LN immune cell proportions, except at terminal stages of 
the  disease  when  the  CD4/CD8  T  cell  ratio  was  significantly  decreased.  We 
performed a test in vitro to assess T cell responsiveness to mitogen and there were 
no differences between transgenic and control mice. We also demonstrated that 
transgenic mouse T cells are able to become activated after vaccination, but we 
did not detect a specific tumour-associated antigen response. 
In  conclusion,  RasB8  glioma  does  not  significantly  influence  RasB8 
peripheral immune status, except at later stages when CD4 T cell proportion is 
compromised. Furthermore, there were no alterations in cell responsiveness and 
activation.  If  these  results  can  be  extrapolated  to  glioma  patients,  they  may 
indicate that peripheral vaccination as part of an immunotherapy may be efficient 
if undertaken at early stages of disease development, or perhaps in patients with 
low  grade  tumours.  However,  anti-glioma  immune  function  will  still  have  to 
occur locally at the tumour site in the brain, and this may be a limiting factor for 
clinical efficacy of a single modality therapy involving vaccination.  
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APPENDIX 
 
 
Media and buffers 
 
ACK buffer  Lysis  buffer  (FULKA);  NH4Cl  8.26  g/l,  KHCO3  1  g/l, 
EDTA 37 mg/l. 
 
FCS   Fetal  Calf  Serum  (GIBCO,  Invitrogen);  complement-
inactivated (56°C for 30 minutes). 
 
Fix/Perm Solution  fixation/permeabilization solution (BD Cytofix/CytopermTM 
Plus Fixation/Permeabilization kit). 
 
FWB  Flow cytometer Wash Buffer (PBS 1x supplemented with 
sodium azide 0.05%, FCS 5%). 
 
FWB fix   Flow  cytometer  Wash  Buffer  with  Fixative  (PBS  1x 
supplemented  with  BSA  0.5%,  sodium  azide  0.05%, 
formaldehyde 1%). 
 
Golgi Stop  protein  transport  inihibitor  containing  monensin  (BD 
Cytofix/Cytoperm
TM Plus Fixation/Permeabilization kit).  
 
HBSS medium  Hanks  Balanced Salt Solution  1x (Invitrogen), containing 
Hepes  10mM,  Penicillin  100  μg/ml,  Streptomycin  100 
U/ml. 
 
Perm/Wash Buffer  stock 10x, (diluited at 1x in distillated autoclaved water for 
use);  containing  Fetal  Bovine  Serum  and  saponin  (BD 
Cytofix/Cytoperm
TM Plus Fixation/Permeabilization kit).  
 
RPMI medium  (Invitrogen), Roswell Park Memorial Institute medium 1640 
(1x). 
 
TBE buffer   GIBCO (Invitrogen). Containing Tris 1M, Boric Acid 0.9 
M,  EDTA  0.01  M.  Stock  at  10x,  diluted  in  distillated 
autoclaved water to prepare TBE 1x.  
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T cell medium   500  ml  DMEM  (Dulbecco’s  Modified  Eagle’s  Medium) 
high  glucose  (4500  mg/ml)  containing  Glutamax  and 
Pyruvate  +  FCS  6%  +  Hepes  10  mM  +  Penicillin  100 
μg/ml,  Streptomycin  100  U/ml,  L-Glu  2  mM,  L-arg  116 
mg/l, Asp 36 mg/l + β-ME 2x10
-5
 M. 
 
 
Fluorochromes 
 
 
APC      Allophycocyanin 
APC/ Cy 7     APC and cyanine dye Cy 7 
FITC       Fluorescein isothiocyanate 
PE      Phycoerythrin 
PE/ Cy 7    PE and cyanine dye Cy 7 
Per CP/Cy 5.5    Peridinin chlorophyll protein and cyanine dye Cy 5.5 
SA       Streptavidin 
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